Determinants of Cognitive Decline and Dementia in the Very Old by Euser, S.M. (Sjoerd)
 Determinants of
 Cognitive Decline and
 Dementia in the
  Very Old
Sjoerd Marijn Euser
Acknowledgements
The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University 
Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands 
Organization for Health Research and Development (ZonMw), the Research Institute for 
Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry 
of Health, Welfare and Sports, the European Commission (DG XII), and the municipality of 
Rotterdam. The contributions of the general practitioners and pharmacists of the Ommoord 
district to the Rotterdam Study are greatly acknowledged. The work described in this thesis 
was supported by the Netherlands Organization for Scientific Research (NWO), Research In-
stitute for Diseases in the Elderly (RIDE) grants 948-00-009 and 948-00-021, by the Alzheimer’s 
Association grant IIRG-06-27261 and by the International Foundation Alzheimer’s Research.
The publication of this thesis was financially supported by the department of Epidemiology 
of the Erasmus Medical Center Rotterdam and by Alzheimer Nederland.
Printed by Optima Grafische Communicatie, Rotterdam
ISBN 978-90-8559-450-5
Cover design: Jan Nijland
© Sjoerd Euser, 2008
No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any 
form or by any means, without permission of the author or, when appropriate, of the pub-
lisher of publications.
Determinants of Cognitive Decline 
and Dementia in the Very Old
Determinanten van Cognitieve Achteruitgang 
en Dementie in de Oudste Ouderen
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties
de openbare verdediging zal plaatsvinden op
woensdag 17 december om 9:45 uur
door
Sjoerd Marijn Euser
geboren te Herveld
Promotiecommissie
Promotoren: Prof.dr. M.M.B. Breteler
 Prof.dr. R.G.J. Westendorp
Overige leden: Prof.dr. J.C.M. Witteman
 Dr. G.J. Biessels
 Prof.dr. J. Gussekloo
 Dr. E.J.G. Sijbrands
 Dr. A.J.M. de Craen
5Contents
1. introduction 7
2. measuring cognitive function
2.1 Measuring cognitive function with age: the influence of selection by health 
and survival
13
3. glucose metabolism and cognitive function
3.1 A prospective analysis of elevated fasting glucose levels and cognitive 
function in older people
31
3.2 Genetic influence on insulin/IGF-1 signaling and cognitive function 47
4. Vascular and inflammatory factors and cognitive function
4.1 The effect of age on the association of blood pressure with cognitive function 
later in life
59
4.2 Systemic markers of inflammation and cognitive decline in old age 71
4.3 Serum uric acid and the risk of dementia 89
5. markers for cognitive decline
5.1 Plasma amyloid beta peptides and the risk of cognitive decline 101
6. general discussion 111
7. summary 127
6Manuscripts based on the studies described in this thesis
chapter 2.1
Euser SM, Schram MT, Hofman A, Westendorp RGJ, Breteler MMB. Measuring cognitive func-
tion with age: the Influence of Selection by Health and Survival. Epidemiology 2008;19:440-
447.
chapter 3.1
Euser SM, Sattar N, Witteman JCM, Bollen ELEM, Sijbrands EJG, Hofman A, Perry IJ, Breteler 
MMB, Westendorp RGJ for the PROSPER and Rotterdam studies. A prospective analysis of 
elevated fasting glucose levels and cognitive function in older people: results from the PROS-
PER and Rotterdam studies. Submitted.
chapter 3.2
Euser SM, Van Heemst D, Van Vliet P, Breteler MMB, Westendorp RGJ. Insuline/Insulin-like 
Growth Factor-1 signaling and cognitive function in humans. J Geront A Biol Sci Med Sci 
2008. Journal of Gerontology Series A, Biological Sciences and Medical Sciences (in press).
chapter 4.1
Euser SM, Van Bemmel T, Schram MT, Gussekloo J, Hofman A, Westendorp RGJ, Breteler MMB. 
The effect of age on the association of blood pressure with cognitive function later in life. 
Submitted.
chapter 4.2
Schram MT, Euser SM, De Craen AJM, Witteman JCM, Frölich M, Hofman A, Jolles J, Breteler 
MMB, Westendorp RGJ. Systemic markers of inflammation and cognitive decline in old age. 
Journal of the American Geriatrics Society 2007;55:708-16.
chapter 4.3
Euser SM, Hofman A, Westendorp RGJ, Breteler MMB. Serum uric acid and cognitive function 
and dementia. Submitted.
chapter 5.1
Euser SM, Schram MT, Soares HD, Hofman A, Westendorp RGJ, Breteler MMB. Association 
between plasma Aβ1-42 and Aβ1-40 and cognitive decline and dementia. Submitted.
1
Introduction

9Introduction
Ch
ap
te
r 1
The gradual but increasing decline of cognitive abilities is arguably one of the most devastat-
ing features that accompany the aging process. This loss of cognitive function in the elderly 
is often considered intrinsic to “normal aging”; a disputable view as the regular occurrence of 
impaired cognitive function does not directly imply inevitability.
Especially in the very old, there is accumulating evidence that a variety of causes, rather than 
a single factor, result in impaired cognitive function and the clinical symptoms of dementia.1 
This “mixed pathology” was shown in post mortem studies and emphasizes the multifactorial 
and heterogeneous nature of the dementia syndrome.1,2 Vascular factors, inflammation fac-
tors, endocrine factors and lifestyle factors have been shown to be associated with the risk of 
dementia in elderly populations.3
Many studies on the etiology of dementia have focused on the distinction between de-
mented and non-demented persons. Although the choice for this clinically based definition 
has undoubtedly improved our understanding of the biological mechanisms that underlie 
the development of dementia, it is unlikely that the gradually progressing character of cogni-
tive decline that often precedes clinical dementia is adequately reflected by this distinction. 
Furthermore, the complex diagnosis of the clinical syndrome of dementia, that is character-
ized by criteria including both decline in cognitive abilities and its interference with activities 
of daily living, might not always be specific enough.
Studying changes in cognitive function in the developmental stage of dementia may not 
only better represent the underlying biology of the disease but could possibly lead to the 
identification of risk factors in the early stages of the disease process.
One would expect that the occurrence of impaired cognitive function in predominantly 
the oldest old individuals, and the concurrently large potential gain in experienced health 
in this group, would have increased the focus on biological mechanisms involved in the de-
velopment of cognitive impairment in especially these oldest old. In most studies however, 
there is a clear underrepresentation of oldest old individuals.
A particular research interest regarding the development of cognitive decline and demen-
tia is the identification of potentially modifiable risk factors, including factors involved in 
glucose metabolism, vascular pathology and inflammation.
The relation between impaired glucose metabolism and cognitive impairment, in for in-
stance diabetes mellitus patients, could be explained by concurrent cerebrovascular disease, 
accumulation of advance glycation end-products (AGE) or disruption of amyloid β clear-
ance.4-6 However, the relation between a pre-diabetic state, when impaired fasting glucose 
levels are present, and cognitive function and decline needs further clarification.
Furthermore, vascular pathology in general has been shown to play a prominent role in 
the development of dementia.3,7 Cerebral small vessel disease, stroke and disturbed cerebral 
perfusion could underlie this association.7,8 Several other lines of investigation have addi-
tionally suggested a role for inflammation in the development of cognitive impairment and 
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dementia.9,10 How these vascular and inflammatory risk factors relate to cognitive function in 
the early stages of the disease remains to be investigated.
Next to the investigation of these potentially modifiable risk factors for cognitive impair-
ment and dementia, there is an increasing interest in research on preclinical markers of 
dementia that could be used to identify people who are at increased risk of developing 
dementia. Serum levels of amyloid β peptides have already been suggested as biomarkers 
for dementia,11 although the relation between the peptide levels and the risk of dementia 
and cognitive decline warrants further research.
Moreover, there have been studies that suggest that in general, possible risk factors that 
play a role at younger ages may not be important anymore when people survive until higher 
ages.12,13 To examine the potential age-specific effects of these risk factors, studies with larger 
numbers of oldest old participants are needed. I was in the fortunate position to have the 
availability over several large prospective studies including the Rotterdam Study,14 the Lei-
den 85-plus Study,15 and the PROSPER study,16 that were complementary with respect to the 
age of the participants and consequently provided me with the tools to study the association 
between several potentially modifiable risk factors and cognitive function and decline over a 
wide age range in the general population.
The Rotterdam Study is a large population-based prospective study that was conducted 
among 7,983 inhabitants of Ommoord, a district of Rotterdam, aged 55 years and older.14 The 
study was designed to target cardiovascular, neurological, opthalmological and endocrine 
diseases and is ongoing since 1990. All participants underwent baseline examinations (1990-
1993) and were invited to visit the research center during follow-up examinations (1993-1994, 
1997-1999, 2002-2004) where cognitive function was assessed with a neuropsychological 
test battery.
The Leiden 85-plus Study is a prospective population-based study of 85-year-old inhabit-
ants of Leiden.15 Between September 1997 and September 1999, all inhabitants of Leiden 
born between 1912 and 1914 were contacted within a month of their 85th birthday, and 599 
individuals agreed to participate. Annual follow-up examinations were performed until age 
90, during which cognitive function was assessed.
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a prospective mul-
ticenter randomized placebo-controlled trial to assess whether treatment with pravastatin 
diminishes the risk of major cardiovascular events in the elderly.16 Between December 1997 
and May 1999, a total of 5,804 participants (aged 70-82 years) with an increased risk of cardio-
vascular disease were recruited in Scotland, Ireland and the Netherlands. Cognitive function 
was assessed at baseline, after 9, 18 and 30 months, and at the end of the study (between 36 
and 48 months) with a dedicated neuropsychological test battery.
In this thesis, I first explored the measurement of cognitive function, with respect to the ef-
fect of selection by health and survival on the estimation of cognitive function and decline 
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in epidemiological studies. I used several study designs and methods to handle multiple 
and missing data to investigate how these affected the estimates of cognitive function and 
decline in our study populations. This work is described in chapter 2.
In chapter 3, I examined the relation between glucose metabolism and cognitive function 
and decline. First, I investigated the association between fasting glucose levels and cogni-
tive function and decline in a combined study of data from the Rotterdam Study and the 
PROSPER study. Additionally, I studied the association between genetic variation in genes 
that influence insulin/IGF-1 signaling and cognitive function in the Leiden 85-plus Study. The 
insulin/IGF-1 signaling pathway has previously been shown to be involved in the regulation 
of health and lifespan in a number of model organisms and humans, although its relation 
with cognitive function has thus far not been extensively studied.
In chapter 4, I investigated the association between several vascular and inflammatory 
risk factors and cognitive function and decline. First, I investigated how age influences the 
relation between blood pressure and cognitive function, using pooled data from both the 
Rotterdam Study and the Leiden 85-plus Study which provided a large sample of participants 
over a broad age range. Second, I studied the association between circulating markers of 
inflammation and cognitive function and decline in a combined analysis of data from the 
Rotterdam Study and the Leiden 85-plus Study. Inflammation has been suggested to be 
involved in the pathogenesis of dementia by several lines of research, although the relation 
between inflammatory processes and cognitive function in the early stages of the develop-
ment of the disease is not clear yet. Third, I described the association between serum uric 
acid and cognitive function and dementia. Serum uric acid is a well known risk factor for 
cardiovascular disease and stroke, but is also thought to possess beneficial properties, as 
it accounts for a substantial part of the antioxidative capacity of the plasma. These seem-
ingly contradictory properties with respect to the development of cognitive impairment and 
dementia are addressed in this chapter.
In chapter 5, I examined potential biomarkers that are suggested for the identification 
of people who are at increased risk of developing dementia. Senile plaques in the brain of 
Alzheimer’s disease patients are a characteristic hallmark of this disease and predominantly 
contain amyloid peptides. Serum levels of these amyloid β peptides have been associated 
with an increased risk of dementia and the plasma Aβ1-42/Aβ1-40 ratio has been suggested as 
a premorbid biomarker for dementia. I have further examined the relation between serum 
amyloid β peptides and cognitive decline in the early stages of the development of demen-
tia.
Finally, in chapter 6, I acknowledged several methodological issues that were related to the 
work described in this thesis and discussed some suggestions for further research.
Chapter 1
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2.1
Measuring Cognitive Function with Age: 
the Influence of Selection by Health and Survival
ABstrAct
Background: Research into the pathophysiology of age-associated cognitive function and 
decline requires a valid estimate of cognitive function. However, this estimation can be 
grossly influenced by a selective loss to follow-up.
methods: We investigated the influence of health selection on the estimated age-associated 
cognitive function and decline by studying the effect of study design and the handling of 
multiple and missing data on this estimation. We used linear regression analyses and linear 
mixed models to assess cognitive function from cross-sectional and longitudinal data. Re-
peated measures of cognitive function (assessed with dedicated neuropsychological tests) 
were carried out in two independent population-based cohort studies: the Rotterdam Study 
(3719 participants, mean age 71 years) and the Leiden 85-plus Study (369 participants, age 
85 years).
results: The effect of age on cognitive function was greater in cross-sectional analyses 
when all participants were included than when analyses were restricted to participants with 
repeated measurements. The decline in cognitive function over 4.6 years of follow-up was 
intermediate between the cross-sectional estimates from the total and from the restricted 
sample. Moreover, the estimated decline in cognitive function was larger when using a short 
follow-up than when using the complete follow-up over 5 years. The estimated decline using 
linear mixed models was similar to analyses including those with a complete follow-up over 
5 years.
conclusion: Selection for health and survival results in better age-specific cognitive test 
scores and less cognitive decline. Statistical methods handling multiple and missing data do 
not fully correct for this bias.
Chapter 2.1
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introdUction
Cognitive function decreases with age. The investigation of causes of age-associated cogni-
tive function and decline requires a valid estimate of deterioration in cognitive function.
Previous population-based studies that estimated cognitive function over time have 
yielded diverse results. The variety in estimates has been ascribed to differences in study 
population, assessment of cognitive function and statistical analysis technique.1-7 Another 
important contribution to these discrepancies could come from selection bias, which is a 
common problem in the study of longitudinal estimates in epidemiologic settings.8-10
The objective of the present study was to examine the effect of health selection on the 
estimated cognitive decline in a population-based setting. In particular, we examined the 
influence of cross-sectional versus longitudinal designs, and the influence of various ways to 
handle multiple and missing data. We examined these issues in two independent population-
based studies: the Rotterdam Study and the Leiden 85-plus Study.
metHods
Population
The Rotterdam Study is a large prospective population-based cohort study that is being con-
ducted among all inhabitants aged 55 years and over of Ommoord, a district of Rotterdam, 
The Netherlands.11 The medical ethics committee of the Erasmus University of Rotterdam 
approved the study, and informed consent was obtained from all participants. A total of 7983 
individuals (response rate 78 percent) participated in the baseline examinations between 
1990-1993 (mean age 71, range 55-106 years). All participants were interviewed at home, 
and visited the research center for further examinations. In the 3rd survey (1997-1999) and the 
4th survey (2002-2004) cognitive function was assessed more extensively with a dedicated 
neuropsychological test battery.
The Leiden 85-plus Study is a prospective population-based cohort study of inhabitants of 
Leiden, The Netherlands. The medical ethics committee of the Leiden University Medical Cen-
tre approved the study, and informed consent was obtained from all participants. Between 
September 1997 and September 1999, all inhabitants of Leiden born between 1912 and 1914 
(n=705) were contacted within a month after their 85th birthday. A total of 599 individuals 
(response rate 87 percent) agreed to participate. Over the next 5 years (until the age of 90), 
annual neuropsychological tests were performed during home visits.
Study sample
In the Rotterdam Study, 4797 individuals participated in the 3rd survey, of whom 4206 under-
went the neuropsychological test battery. Complete data on all tests in the neuropsychologi-
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cal test battery were available for 3865 participants. Of these, 2470 also had complete data on 
all cognitive tests at the 4th survey. Of the remaining 1395 persons with no or incomplete data 
for the 4th survey, 31 percent had died, 40 percent declined to participate or were too ill to visit 
the research centre, 7 percent could not be contacted and 22 percent had incomplete data 
on the neuropsychological test battery. We restricted the analyses to participants younger 
than 85 years, because of the relatively limited number of participants above this age. This 
resulted in a study sample of 3719 participants at the 3rd survey available for cross-sectional 
analyses, and 2441 participants with repeated measurements available for longitudinal 
analyses. The proportion of participants without follow-up was especially high among those 
oldest at baseline (for baseline age 60-64 years, 22.4% had no follow-up information; 65-69 
years, 22.4% ; 70-74 years, 33.2% ; 75-79 years, 48.2% ; 80-84 years, 65.7%).
In the Leiden 85-plus Study, 599 participants underwent neuropsychological testing at 
age 85, and 446 had complete data on all tests in the neuropsychological test battery. Of 
these, 369 also had complete data on the neuropsychological test battery at age 86 and 
were therefore available for comparison among the methods for handling missing data in 
a longitudinal study design. For 158 participants, annual data on the neuropsychological 
test battery during the entire 5-year follow-up period were available. Of the remaining 288 
persons who did not participate, 59 percent died, 11 percent declined to participate and 30 
percent had incomplete data on the neuropsychological tests.
Cognitive function
Global cognitive function was measured by use of the Mini-Mental State Examination in both 
cohorts. In addition, a dedicated neuropsychological test battery was used to assess execu-
tive function and memory function. Executive function was assessed by use of the abbrevi-
ated Stroop test trial 3 and the Letter Digit Substitution Task in both cohorts and by use of 
the Word Fluency Test in the Rotterdam Study. Memory function was assessed in the Leiden 
85-plus Study only, by use of the 12-Picture Learning Test (immediate and delayed recall).
The Mini-Mental State Examination is a widely used test developed as a screening instru-
ment for dementia; it provides a reliable measure of global cognitive function.12-14 The Letter 
Digit Substitution Task is a modified version of the Symbol Digit Modalities Test, measuring 
processing speed.15 Participants make as many letter-digit combinations as possible within 60 
seconds, following an example that shows the correct combinations. The abbreviated Stroop 
test is a measure of attention, consisting of three trials in which the participant has to name 
40 items shown on a card.16,17 In trial 1 the card contains color-names printed in black and 
participants are asked to name the printed word. In trial 2 the card contains colored blocks 
and participants are asked to name the printed color. In trial 3 the card contains color-names 
printed in a different color than the color-name and participants are asked to name the color 
of the ink. The outcome variable is the time needed to finish trial 3. The Word Fluency Test is 
a test for verbal fluency as an element of executive function. Participants are asked to name 
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as many animals as possible within 60 seconds.18 Memory function was assessed by the 
12-Picture Learning Test, a measure of memory function with immediate- recall and delayed- 
recall components.19 In the immediate recall portion, participants are shown pictures of 12 
different objects and then asked to recall as many as possible. This is done three consecutive 
times with the total number of correct answers as the outcome variable. After 20 minutes the 
participants are asked again to recall the 12 objects. This number is the outcome variable for 
the delayed recall.
Additional measurements
In the Rotterdam Study, education was measured at the baseline examination (1990-1993), 
and dichotomized into more or less than primary education. In the Leiden 85-plus Study, 
education was assessed at age 85 years, and also dichotomized into more or less than primary 
education.
Statistical analyses
Estimates of cross-sectional and longitudinal analyses
Age-associated cognitive function was estimated from both cross-sectional and longitudinal 
analyses in the Rotterdam Study. In the cross-sectional analyses, we first calculated cognitive 
test scores at the 3rd survey in the total sample, in the sample of participants who were alive at 
follow-up regardless of whether they participated or not, and in the participants who partici-
pated at follow-up; we then compared those results, for consecutive 5-year age categories. In 
the longitudinal analyses, we compared cognitive test scores at the 3rd survey with those at 
the 4th survey within 5-year age categories.
The longitudinal decline in cognitive function over 1-year periods was examined in the 
sample of the Leiden 85-plus Study (from age 85 to 86, 86 to 87, 87 to 88, 88 to 89 and 89 to 
90 years). For every 1-year period, we selected participants with complete data on cognitive 
tests at the beginning and the end of the one-year interval. The difference in cognitive func-
tion between those two examinations was compared.
Handling of multiple and missing data
We evaluated the effects of four different ways of handling multiple and missing data on the 
estimated rate of cognitive decline in the sample of the Leiden 85-plus Study.
First, we assessed the one-year change in cognitive function by comparing test scores at 
baseline (age 85 years) with test scores after one year of follow-up (age 86 years). We selected 
those participants with complete data at age 85 and at age 86 years, and calculated the dif-
ference in cognitive function between age 85 and 86 years. Second, we assessed the annual 
change in cognitive function by comparing test scores at baseline (85 years) with those at 
the last available follow-up visit. Annual change in cognitive function was calculated as the 
difference between test score at baseline and test score at the last available year of follow-
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up, divided by the length of follow-up (1-5 years). Third, we assessed the annual change in 
cognitive function for participants with a complete annual follow-up from age 85 to 90 years, 
using a linear regression analysis with cognitive function as dependent and age as indepen-
dent variable. Fourth, we assessed the annual change in cognitive function by use of a linear 
mixed model. The linear mixed model uses all available data during follow-up to assess the 
annual change in cognitive function. All participants with at least 1 year of follow-up were 
included in these analyses.
resUlts
Table 1 shows the baseline characteristics of both study samples. In the Rotterdam Study at 
the 3rd survey (baseline for these analyses) the mean age of the participants was 71.4 years, 
58 percent were women, and 28 percent had primary education at most. Mean follow-up was 
4.6 years. Participants with a follow-up examination were slightly younger and had a better 
cognitive function at the 3rd survey (Mini-Mental State Examination-score [range]: 28.1 points 
[18-30]) compared with participants without at least one follow-up examination (Mini-Mental 
State Examination-score [range]: 27.8 [13-30]). In the Leiden 85-plus Study age at baseline 
was 85 years, 65 percent of participants were women and 56 percent had primary education 
only. Those participants who were followed for 5 years had a better cognitive function (Mini-
Mental State Examination-score [range]: 27.4 points [20-30]) than participants in the total 
sample (Mini-Mental State Examination-score [range]: 26.7 points [19-30]). Additionally, in 
both the Rotterdam Study and the Leiden 85-plus Study, a smaller proportion of the partici-
pants with a follow-up examination had a history of myocardial infarction and cardiovascular 
accident compared to participants without at least one follow-up examination.
Estimates from cross-sectional and longitudinal analyses
Figure 1 presents the cross-sectional cognitive test scores in consecutive age categories at 
the 3rd survey in the Rotterdam Study for the total sample, for the sample of participants who 
were alive at follow-up regardless of whether they participated, and for the restricted sample 
of participants for whom repeated measurements were available. The latter group had better 
cognitive test scores in all age categories when compared with the total sample and the 
sample of participants who were alive at follow-up. The difference in cognitive test scores 
between the total and restricted samples increased with age, as is illustrated by the diverging 
dotted lines. Similar patterns were seen for all tests of cognitive function. These findings were 
confirmed by additional analyses, which showed an association between lower cognitive test 
scores and an increased risk of mortality (hazard ratios for mortality [95% confidence interval 
(CI)] per SD increase in cognitive test score were: Mini-Mental State Examination (0.81 [0.76-
0.86]) ; Letter Digit Substitution Task (0.69 [0.63-0.75]) ; Stroop test trial 3 (1.23 [1.16-1.31]) and 
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Word Fluency Test (0.76 [0.70-0.82])) and an association between lower cognitive test scores 
and non-participation (odd ratios for non-participation [95%CI] per SD increase in cognitive 
test score were: Mini-Mental State Examination (0.69 [0.64-0.75]) ; Letter Digit Substitution 
Task (0.68 [0.63-0.75]) ; Stroop test trial 3 (1.35 [1.25-1.47]) and Word Fluency Test (0.76 [0.70-
0.83])).
Figure 2 shows the longitudinal decline of cognitive test scores within 5-year age categories 
in the Rotterdam Study. The age-specific cognitive function is consistently better in partici-
pants at the 3rd survey than in participants of the same age at the 4th survey. The longitudinal 
decline in cognitive function over a 4.6-year follow-up period is stronger compared with the 
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Figure 1.
A 
C D
B 
        Total sample 
       Sample alive at follow-up 
       Sample with follow-up  
Figure 1. Results for (A) the Mini-Mental State Examination (MMSE), (B) the Letter Digit Substitution Task 
(LDST), (C) the Stroop test trial 3 and (D) the Word Fluency Test. Note that in the Stroop test trial 3 (C) a 
higher score indicates a worse cognitive function. Error bars represent standard errors of the mean.
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cross-sectional estimates of the same sample. This effect was more pronounced at older ages. 
All tests scores of cognitive function were similarly affected.
Figure 3 shows the longitudinal decline of cognitive test scores over 1-year periods in the 
Leiden 85-plus Study. This figure shows a similar (though more extreme) pattern compared 
with that in figure 2. The age-specific cognitive function at the beginning of the 1-year pe-
riods is better than in participants of the same age at the end of the 1-year periods. Again, 
for all tests of cognitive function, age-specific test scores were better when based solely on 
participants with follow-up examinations.
Handling of multiple and missing data
Table 2 shows the annual decline in cognitive function as estimated by different statistical 
handling of the data in the Leiden 85-plus Study. The estimated decline in cognitive function 
Pagina 22:  
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            Decline in test score between 3rd and 4th survey 
Figure 2. Results for (A) the Mini-Mental State Examination (MMSE), (B) the Letter Digit Substitution 
Task (LDST), (C) the Stroop test trial 3 and (D) the Word Fluency Test. The solid lines show the decline in 
cognition over 4.6 years per age category.
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was larger when using a shorter rather than a longer follow-up. Cognitive decline was also 
estimated to be larger when using only the data at baseline together with the latest follow-
up data, compared with the decline estimated from the complete annual follow-up over 5 
years. The decline in cognitive function when using linear mixed models was similar to that 
estimated by use of complete follow-up data.
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Figure 3. Results for (A) the Mini-Mental State Examination (MMSE), (B) the Letter Digit Substitution Task 
(LDST), (C) the Stroop test trial 3, (D) the 12-Picture Learning Test immediate recall (12-PLT immediate 
recall) and (E) the 12-Picture Learning Test delayed recall (12-PLT delayed recall). The number of 
participants in each 1-year period varies per year; age 85-86 (n=369), 86-87 (n=315), 87-88 (n=265), 88-89 
(n=210), 89-90 (n=164).
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discUssion
Estimated cognitive function is better when the analyses are based on participants for whom 
follow-up examinations are available. Moreover, longer follow-up periods further diminish 
the rate of decline. Estimates from linear mixed models analyzing all individuals with different 
follow-up periods were not materially different from the estimates obtained when analyzing 
data from participants with complete follow-up data.
The strengths of our study include the use of two independent population-based studies. 
The age distributions of the 2 cohorts were complementary and allowed us to study the 
change in cognitive function from age 60 till 90 years. The dedicated neuropsychological 
tests used in both populations were comparable and assessed several cognitive domains. 
However, extensive data on cognitive function in the Rotterdam Study were available only for 
the 3rd and the 4th survey, resulting in a follow-up of just 4.6 years. A longer follow-up period 
could give more insight into the effect of health-selection on the estimated age-associated 
cognitive function in the different study designs.
Our data show that the various study designs resulted in different estimations of age-
associated cognitive function. This is due to selective non-participation and drop-out of 
participants with lower levels of cognitive function. In a cross-sectional setting, difference 
in cognitive function in population-based studies depends highly on response rate. In a 
longitudinal setting, the estimated decline in cognitive function depends on response rate, 
drop-out during follow-up and the statistical method used to handle multiple and missing 
data. The selection for health and survival is the overriding phenomenon that results in the 
different estimates for the age-associated cognitive function in both study designs.
Sample selection has an important effect on the outcomes of a study. A cross-sectional 
design will estimate cognitive function in the relatively healthy part of the population; non-
participants tend to have lower cognitive function and are less healthy than participants.6,20,21 
This effect was confirmed by our data that showed a smaller proportion of participants with 
table 2. Estimates of annual change in cognitive function derived from different methods for handling 
multiple and missing data in the Leiden 85-plus Study.
Neuropsychological tests Annual change in cognitive function (95% CI)
Short follow-up
(1 year)
Maximal follow-up
(1-5 years)
Complete follow-
up (5 years)
Mixed models
(1-5 years)
(n=369) (n=369) (n=158) (n=369)
MMSE (points) -0.3 (-0.5, -0.1) -0.4 (-0.6, -0.3) -0.2 (-0.3, -0.2) -0.3 (-0.4, -0.3)
LDST(correct answers) -0.6 (-1.0, -0.2) -0.9 (-1.1, -0.7) -0.6 (-0.8, -0.5) -0.7 (-0.8, -0.6)
Stroop test trial 3 (seconds)  1.9 (-0.8, 4.6)  1.4 (-0.4, 3.1)  1.5 (0.9, 2.1)  1.6 (1.0; 2.1)
12-PLT immediate recall 
(pictures)
-2.2 (-2.7, -1.8) -1.6 (-1.9, -1.4) -0.8 (-1.0, -0.7) -1.0 (-1.1, -0.9)
12-PLT delayed recall 
(pictures)
-1.1 (-1.2, -0.9) -0.8 (-0.9, -0.7) -0.4 (-0.5, -0.3) -0.5 (-0.5, -0.4)
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a history of myocardial infarction and cardiovascular accident, and a smaller difference in 
cognitive function between age categories in the sample with repeated measures compared 
with the total sample. Health related-selection affects not only cross-sectional study designs 
but also longitudinal designed studies. The drop-outs during follow-up were not random, but 
consisted predominantly of older participants with lower cognitive function. In a longitudinal 
study the participants at baseline are a relatively healthy selection of the total population 
and the participants who complete follow-up are a further selection of these participants.
Cross-sectional results are generally considered inferior to longitudinal ones, but this may 
not be the case if longitudinal data are distorted by deaths and drop-outs during follow-up.
The 4 ways we used to handle multiple and missing data resulted in different estimates of 
cognitive decline. Either a short or a maximal follow-up produced a higher estimated cogni-
tive decline than a complete follow-up. This suggests that the participants who dropped out 
during follow-up have a larger decline in cognitive function than participants who completed 
the follow-up period. Advanced statistical models such as linear mixed models take missing 
data during follow-up into account in longitudinal data analysis.22-24 However, linear mixed 
models assume that missing data are ”missing at random” or “missing completely at random,” 
which is not always true for longitudinal studies on cognitive function. Our data showed 
that the estimated cognitive decline assessed by a linear mixed model was similar to that 
based on the participants with a complete follow-up over 5 years. Thus, a linear mixed model 
underestimates the decline in cognitive function in this setting.
The problem of defining meaningful longitudinal estimates in the presence of “censoring 
by death” has been extensively studied in the statistical literature.25-28 One of the suggested 
methods for dealing with missing longitudinal data due to death or drop-out is principal 
stratification – i.e., participants are stratified based on their potential outcome concerning 
death or missingness and the analyses take into account this stratification.25 Another promis-
ing method to account for missing longitudinal data is “joint modeling,” in which both the 
random effects in the longitudinal covariates and the survival components are simultane-
ously modeled.29,30 Application of such methods may possibly help overcome some of the 
biases due to health selection in longitudinal epidemiologic studies.
In conclusion, health-related selection artificially elevated age-specific cognitive test scores 
and lowered the estimated slope of age-associated cognitive function, in both cross-sectional 
and longitudinal study designs. In addition, the length of follow-up can affect the estimation 
of cognitive decline, with a short follow-up resulting in a larger estimated rate of decline than 
a longer follow-up period. Even advanced statistical methods such as linear mixed models 
do not adequately account for selective attrition. Assessments of cognitive function in the 
elderly must take particular care in considering possible biases from health selection.
Chapter 2.1
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3.1
A Prospective Analysis of Elevated Fasting 
Glucose Levels and Cognitive Function in Older People: 
Results from the PROSPER and Rotterdam Studies.
ABstrAct
context: Diabetes mellitus is strongly associated with cognitive impairment in older people. 
However, the link between elevated fasting glucose levels and insulin resistance in non-
diabetics and the risk of cognitive impairment is unclear.
objective: To investigate the relation between fasting glucose levels, and insulin resistance, 
and cognitive impairment in old age.
design, setting, and Participants: We analyzed two independent prospective studies: the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER): 5536 participants, age 
69-84 years, and the Rotterdam Study: 3547 participants, age 61-97 years. Fasting glucose 
levels were assessed at baseline in both studies, fasting insulin levels were assessed in the 
Rotterdam Study only. Cognitive function was assessed at baseline and during follow-up.
main outcome measures: Neuropsychological test battery to assess executive function and 
memory.
results: Subjects with diabetes had impaired cognitive function at baseline and over time. In 
contrast, there was no clear association between baseline fasting glucose levels and executive 
function and memory in people without a history of diabetes, neither in the PROSPER study 
nor in the Rotterdam Study. No consistent relation existed between elevated baseline fasting 
glucose levels and the rate of cognitive decline in either cohort. Insulin resistance (HOMA 
index) was also unrelated to cognitive function and decline. The results did not change after 
additional adjustment for BMI, systolic and diastolic blood pressure, HDL-cholesterol and 
APOE-genotype.
conclusion: Elevated fasting glucose levels and insulin resistance are not associated with 
worse cognitive function in older people without a history of diabetes. These data suggest 
either a threshold for effects of dysglycaemia on cognitive function, or that factors other than 
hyperglycaemia impair cognition in individuals with frank diabetes.
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introdUction
Diabetes has been shown to be associated with an increased risk of dementia and impaired 
cognitive function.1-5 Suggested biological mechanisms that are involved in this relation are: 
an indirect relation through cerebrovascular disease,2,5,6 accumulation of advanced glycation 
end-products (AGE),7 and reduced amyloid β clearance through disturbing the role of the 
insulin-degrading enzyme.8
The accumulating evidence that diabetes mellitus is involved in a number of health prob-
lems ranging from retinopathy and cardiovascular symptoms to neurological complications, 
has started a discussion about the necessity to identify those people who are at increased 
risk for diabetes.8-14
Classifying people based on levels of fasting glucose to indicate “impaired fasting glucose” 
has been suggested as a possible tool for risk assessment of gestational diabetes mellitus.11,13 
However, the relation between the preceding stage of diabetes, when impaired fasting 
glucose levels are present, and cognitive function has not been comprehensively elucidated. 
A number of studies have investigated the relation between this “pre-diabetes” state and 
cognitive function but showed contradictory or inconclusive results,4,15-17 possibly due to 
relatively small sample sizes and limited numbers of participants with an impaired fasting 
glucose level.4 Alternatively, peripheral insulin resistance that could underlie the elevated 
fasting glucose levels in the “pre-diabetes” state may contribute to impaired cognitive func-
tion.18,19
Therefore, in this study we investigated the association between fasting glucose levels 
and cognitive function and decline in a large sample of 9083 participants for whom fasting 
glucose levels at baseline were available together with longitudinal data from a dedicated 
neuropsychological test battery. Additionally, we investigated the relation between insulin 
resistance (using the HOMA index) and cognitive function and decline in 3452 participants.
metHods
Populations
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a prospective 
multicenter randomized placebo-controlled trial to assess whether treatment with pravasta-
tin diminishes the risk of major cardiovascular events in the elderly.20,21 Between December 
1997 and May 1999, a total of 5804 participants (aged 70-82 years) with pre-existing vascular 
disease or increased risk of such disease due to a history of smoking, hypertension, or diabe-
tes, were recruited in Scotland, Ireland and the Netherlands. The institutional ethics review 
boards of all centres approved the protocol, and all participants gave written informed 
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consent. Participants with very severe cognitive impairment (Mini-Mental State Examination 
score <24) were excluded for inclusion in the study.
The Rotterdam Study is a large prospective population-based cohort study that is con-
ducted among all inhabitants aged 55 years and over of Ommoord, a district of Rotterdam, 
the Netherlands.22 The medical ethics committee of the Erasmus University of Rotterdam ap-
proved the study, and written informed consent was obtained from all participants. Of 10,275 
eligible subjects, 7983 individuals (78%) participated in the baseline examinations between 
1990-1993 (mean age 71±25, range 55-106). All participants were interviewed at home, and 
visited the research centre for further examinations.
Fasting glucose levels
In PROSPER, fasting glucose levels were assessed at baseline in 5599 of the 5804 participants. 
Of the 5599 participants, 63 did not have cognitive function tests available at baseline. All 
of the resulting 5536 participants had full data available for other cardiovascular risk factors 
including BMI, systolic and diastolic blood pressure and HDL-cholesterol levels at baseline. 
This resulted in a study sample of 5536 participants for PROSPER.
In the Rotterdam Study, fasting glucose levels were assessed at the 3rd survey (1997-1999) 
in 3795 participants. Of these participants, 3664 were free of dementia and 3550 had data 
available for other cardiovascular risk factors including BMI, systolic and diastolic blood 
pressure and HDL-cholesterol levels. Three participants did not have cognitive function tests 
available at the start of the 3rd survey. This resulted in a study sample of 3547 participants for 
the Rotterdam Study. Additionally, in 3452 of these 3547 participants, fasting insulin levels 
were assessed at the 3rd survey.
In both the PROSPER and the Rotterdam sample, fasting glucose levels were addition-
ally measured during follow-up. 5156 of the 5536 participants in the PROSPER sample and 
2414 of the 3547 participants in the Rotterdam sample underwent at least one additional 
measurement of fasting glucose level in addition to the baseline examination. These data 
were used to study the variability of the fasting glucose levels over time and to assess the ap-
propriateness of using a single baseline fasting glucose measurement to assess the relation 
between fasting glucose and cognitive function and decline.
History of diabetes mellitus
At baselinebaseline (PROSPER) or at the 3rd survey (Rotterdam Study), history of diabetes 
mellitus (DM) was defined by self-reported history of diabetes (reporting the use of oral 
antidiabetes medication, the use of insulin, treatment by diet, or registration by a general 
practitioner as having diabetes) in both study samples.
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Cognitive function
Global cognitive function was measured with the Mini-Mental State Examination (MMSE)23 
in both studies. In addition, a dedicated neuropsychological test battery was used to as-
sess executive function and memory. Executive function was assessed with the Letter-Digit 
Substitution Task (LDST)24 and the abbreviated Stroop test part 325 in both studies, and with 
the Word Fluency Test (WFT)26 in the Rotterdam Study only. Memory was assessed with the 
12-Picture Learning Test (12-PLT) immediate and delayed recall,27 in PROSPER only.
In PROSPER, cognitive function was measured at six time points during the study; before 
randomization, at baseline, after 9, 18, and 30 months, and at the end of the study. The time 
point of the last measurement was different for the participants and ranged from 36 to 48 
months. Therefore we performed the analyses with their individual varying time-point but 
report the results for the mean of these time points (at 42 months). The pre-randomized 
measurement was discarded in the analyses to preclude possible learning effects. This re-
sulted in a mean follow-up of 3.2 years. Change in cognitive function could be assessed in 
5245 participants for whom at least one follow-up examination of cognitive function was 
available.
In the Rotterdam Study, cognitive function was assessed at the 3rd survey (1997-1999) and 
additionally at the 4th survey (2002-2004). This resulted in a mean follow-up of 4.6 years. Of 
the 3547 participants of the Rotterdam sample who were present at the 3rd survey, 2657 
remained in the study until the end of follow-up (4th survey) and were available for the as-
sessment of change in cognitive function.
Additional assessments
In both samples, level of education, BMI, systolic and diastolic blood pressure, HDL-cholesterol 
level and APOE ε4 carrier ship were assessed at baseline (PROSPER) or at the 3rd survey (Rot-
terdam Study).
Statistical analyses
The relation between baseline fasting glucose levels and cognitive function and decline was 
assessed by use of linear mixed models. In PROSPER, all analyses were adjusted for age, sex, 
education, country, use of pravastatin, and where appropriate, test version. In the Rotterdam 
Study, all analyses were adjusted for age, sex, and education. Additionally, adjustments were 
made for systolic and diastolic blood pressure, HDL-cholesterol and APOE ε4 carrier ship, and 
stratified analyses were performed in strata of BMI. Analyses were carried out using the SPSS 
statistical package (release 12.0.1; SPSS inc., Chicago, Illinois).
In the Rotterdam Study sample, data on fasting glucose and fasting insulin levels were used 
to calculate the degree of insulin resistance according to the homeostasis model assessment 
(HOMA).28 The HOMA index is calculated by dividing the product of fasting levels of glucose 
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and insulin by a constant, and has been shown to correlate well (r = 0.82, p<0.0001) with the 
euglycemic hyperinsulinemic clamp method.29
resUlts
Table 1 shows the baseline characteristics of the total sample, and for participants with a 
history of diabetes mellitus at baseline (PROSPER) or at the 3rd survey (Rotterdam Study). In 
PROSPER, the fasting glucose levels (SD) differed between the three countries from which the 
participants were enrolled; Scotland 5.63 (1.28) mmol/L, Ireland 5.09 (1.39) mmol/L, and the 
Netherlands 5.76 (1.64) mmol/L. This resulted in a lower mean fasting glucose level for the 
PROSPER study sample compared to that of the Rotterdam Study sample. Participants with a 
history of diabetes had a higher fasting glucose level, BMI, systolic blood pressure and lower 
levels of HDL-cholesterol, compared to participants without a history of diabetes.
table 1. Baseline Characteristics
Total sample History of diabetes
No Yes
ProsPer
 Number 5536 4935 601
 Age, years (SD) 75.3 (3.4) 75.4 (3.4) 75.2 (3.3)
 Female, No (%) 2869 (52) (53) (44)
 Age when leaving school, years (SD) 15.1 (2.1) 15.2 (2.1) 15.0 (2.0)
 MMSE-score, points (SD) 28.0 (1.5) 28.0 (1.5) 27.9 (1.6)
 Fasting glucose levels, mmol/L (SD) 5.45 (1.43) 5.13 (0.81) 8.03 (2.44)
 BMI, kg/m2 (SD) 26.9 (4.2) 26.7 (4.2) 27.9 (4.4)
 Systolic blood pressure, mmHg (SD) 155 (22) 154 (22) 158 (22)
 Diastolic blood pressure, mmHg (SD) 84 (11) 84 (11) 84 (12)
 HDL-cholesterol, mmol/L (SD) 1.28 (0.35) 1.29 (0.35) 1.18 (0.31)
rotterdam study
 Number 3547 3225 322
 Age, years (SD) 72.0 (6.8) 71.8 (6.7) 73.9 (6.9)
 Female, No (%) 57 58 51
 Low level of education, No (%) 29 29 27
 MMSE-score, points (SD) 27.7 (1.9) 27.8 (1.9) 27.6 (1.9)
 Fasting glucose levels, mmol/L (SD) 5.88 (1.34) 5.67 (0.93) 8.09 (2.42)
 Fasting insulin levels, mU/L (SD)a 11.2 (7.8) 10.9 (7.1) 14.6 (12.3)
 Insulin resistance, HOMA (SD)a 3.07 (2.92) 2.83 (2.25) 5.54 (6.10)
 BMI, kg/m2 (SD) 26.8 (3.9) 26.7 (3.9) 27.8 (4.4)
 Systolic blood pressure, mmHg (SD) 143 (21) 143 (21) 149 (21)
 Diastolic blood pressure, mmHg (SD) 75 (11) 75 (11) 74 (11)
 HDL-cholesterol, mmol/L (SD) 1.40 (0.40) 1.41 (0.40) 1.26 (0.39)
Data are presented as mean (SD) or percentage.
a Fasting insulin levels were available for 3452 participants in the Rotterdam Study
Chapter 3.1
36
In PROSPER, fasting glucose levels were assessed during follow-up after 3, 6, 12, 24 and 
36 months, in addition to the baseline assessment. In 3821 participants without a history 
of diabetes, fasting glucose levels were available at baseline and after 36 months of follow-
up. The glucose levels measured at baseline did not dramatically change during follow-up, 
although in general fasting glucose levels seemed to slightly increase over time. The mean 
baseline fasting glucose levels (SD) and fasting glucose levels (SD) after 36 months within the 
quintiles of the fasting glucose distribution were; 4.29 (0.20) mmol/L and 4.77 (0.65) mmol/L 
for the lowest quintile (Q1); 4.70 (0.08) mmol/L and 4.97 (0.50) mmol/L for Q2; 5.00 (0.08) 
mmol/L and 5.23 (0.68) mmol/L for Q3; 5.33 (0.11) mmol/L and 5.45 (0.69) mmol/L for Q4; 
and 6.25 (0.81) mmol/L and 6.28 (1.38) mmol/L for the highest quintile (Q5). In the Rotterdam 
sample, fasting glucose levels were assessed at the 3rd survey as well as at the end of follow-
up (4th survey) in 2257 participants without a history of diabetes. The mean fasting glucose 
levels (SD) at the 3rd survey and fasting glucose levels (SD) at the end of follow-up within the 
quintiles of the fasting glucose distribution were comparable; 4.82 (0.24) mmol/L and 5.07 
(0.39) mmol/L for the lowest quintile (Q1); 5.20 (0.08) mmol/L and 5.36 (0.42) mmol/L for Q2; 
5.50 (0.08) mmol/L and 5.55 (0.50) mmol/L for Q3; 5.84 (0.11) mmol/L and 5.86 (0.57) mmol/L 
for Q4; and 6.74 (0.99) mmol/L and 6.77 (1.42) mmol/L for the highest quintile (Q5).
Of the 5536 participants in the PROPSER sample who were present at baseline, 4410 re-
mained in the study sample until the end of follow-up, 565 withdrew from the study, and 
561 died during follow-up. The 1126 participants who did not stay in the study sample were 
divided over the two groups: 20.0% of the participants without a history of diabetes and 
23.3% of the participants with a history of diabetes dropped out during follow-up. Of the 
3547 participants of the Rotterdam sample who were present at the 3rd survey, 2657 remained 
in the study until the end of follow-up, 520 refused to participate or were too ill to visit the 
research center, and 370 died during follow-up. In the group without a history of diabetes, 
24.1% was not present at the end of follow-up compared to 34.4% of the participants with a 
history of diabetes.
Figure 1 and 2 show the relation between fasting glucose levels and cognitive function 
at baseline (PROSPER) and 3rd survey (Rotterdam Study). Cognitive test scores are shown 
for quintiles of the distribution of fasting glucose levels in participants without a history of 
diabetes, and for participants with a history of diabetes separately. These data indicate that in 
participants without a history of diabetes, a rise in fasting glucose levels in the non-diabetes 
range is not clearly associated with impairment in cognitive function in neither of the study 
samples. This was seen for all cognitive tests, except for the MMSE in the PROSPER sample 
where higher levels of fasting glucose were modestly associated with worse cognitive func-
tion (p-trend = 0.043). Additionally, we compared the cognitive test scores at baseline (PROS-
PER) or 3rd survey (Rotterdam Study) for participants with and without a history of diabetes 
(Figure 1 and 2) and showed that participants with a history of diabetes had worse cognitive 
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function across majority of tests at baseline compared to participants without a history of 
diabetes (p-value <0.05 for all tests except for the MMSE in the Rotterdam Study sample).
In both study samples, there was a limited number of participants (134 in PROSPER and 
167 in the Rotterdam Study) without a history of diabetes who could have been allocated to 
the diabetes mellitus group based on their fasting glucose levels that were ≥ 7.0 mmol/L.11-13 
The choice to include these “new diabetic” participants in either the diabetes mellitus group 
or in the non-diabetic group could have affected our results. Therefore we did both. When 
these “new diabetic” participants were moved from the highest quintile of the fasting glucose 
distribution to the group with a history of diabetes, the trend over MMSE-scores in quintiles 
of fasting glucose in the PROSPER sample was no longer significant (p = 0.081). Moreover, the 
contrast in LDST-score, Stroop test trial 3-score and 12-PLT immediate and delayed recall in 
PROSPER, and the MMSE-score, the LDST-score and the WFT-score in the Rotterdam Study be-
tween the diabetes mellitus group and the participants without diabetes mellitus attenuated.
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Figuur 2. 
Mini Mental State Examination Letter-Digit Substitution Task 
Stroop Test trial 3 Word Fluency Test 
p = 0.292 
p = 0.615  
p = 0.807 
  p = 0.011  
p = 0.258 
p = 0.046  
p = 0.099 
 p = 0.012  
Figure 2. Fasting glucose levels and cognitive function in the Rotterdam Study.
Bars represent cognitive test-scores [SEM] for quintiles of fasting glucose levels in non diabetic 
participants (from lowest (Q1) to the highest (Q5) levels of fasting glucose), and for participants with a 
history of diabetes (DM). Linear mixed models were used, adjusted for age, sex and level of education; 
Estimates are based on the maximum number of participants available per cognitive test; MMSE (n = 
3547), LDST (n = 3492 ), Stroop test trial 3 (n = 3449 ), WFT (n = 3518 ). P-values reflect the trend over the 
quintiles of fasting glucose levels, and the difference between participants without a history of diabetes 
(n = 3225) and participants with a history of diabetes (n = 322).
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Figure 3 and 4 show the results from the longitudinal analyses for both study samples. 
There was no clear association in either study between baseline or 3rd survey fasting glucose 
levels and change in cognitive function during follow-up in participants without a history of 
diabetes. Although in the PROSPER sample higher levels of fasting glucose were associated 
with an increased rate of decline on the Letter-Digit Substitution Task (p-trend = 0.017), this 
was not confirmed in the sample from the Rotterdam Study (p-trend = 0.500). In contrast, 
participants in the highest quintiles of the fasting glucose distribution in the PROSPER 
sample seemed to have a decreased rate of decline in MMSE-score and 12-Picture Learning 
Test delayed recall-score, although this was again, not confirmed in the Rotterdam Study 
sample. Participants with a history of diabetes showed an increased rate of decline on the 
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 Figuur 4. 
Mini Mental State Examination Letter-Digit Substitution Task 
Stroop Test trial 3 Word Fluency Test 
p = 0.368 
 p = 0.369  
p = 0.500 
 p = 0.630  
  p = 0.624 
 p = 0.585  
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Figure 4. Fasting glucose levels and annual change in cognitive function in the Rotterdam Study.
Bars represent annual change in cognitive test-scores [SEM] for quintiles of fasting glucose levels in non 
diabetic participants (from lowest (Q1) to the highest (Q5) levels of fasting glucose), and for participants 
with a history of diabetes (DM). Linear mixed models were used, adjusted for age, sex and level of 
education; Estimates are based on the maximum number of participants available per cognitive test; 
MMSE (n = 2657), LDST(n = 2632 ), Stroop test trial 3 (n = 2610 ), WFT (n = 2639). P-values reflect the trend 
over the quintiles of fasting glucose levels and the DM group and the difference between participants 
without a history of diabetes (n = 2449) and participants with a history of diabetes (n = 208).
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Letter-Digit Substitution Task (p-value = 0.020) and the Stroop test trial 3 (p-value = 0.036), 
compared to participants without a history of diabetes in the PROSPER sample. All other tests 
in both study samples broadly indicated (albeit not significant) an increased rate of cognitive 
decline for participants with a history of diabetes. Relocating “new diabetic” participants from 
the highest quintile of the fasting glucose distribution to the diabetes mellitus group did not 
markedly change these results.
In Figure 5 and 6, the relation between insulin resistance and cognitive function and de-
cline are shown for the 3452 participants of the Rotterdam Study sample for whom fasting 
insulin levels were available. The homeostasis model assessment (HOMA) that was calculated 
for these participants was correlated with the fasting glucose levels (r = 0.54, p < 0.001), 
although the overlap between quintiles of the HOMA index and quintiles of fasting glucose 
levels was limited: only 35% of the participants without a history of diabetes were in the same 
quintile of the distribution for both fasting glucose and HOMA index. The relation between 
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 Figuur 5. 
Mini Mental State Examination Letter-Digit Substitution Task 
Word Fluency Test 
p = 0.733 
p = 0.570 
p = 0.955 
  p = 0.029  
p = 0.029 
 p = 0.021  
Stroop Test trial 3 
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Figure 5. Insulin resistance (HOMA) and cognitive function in the Rotterdam Study.
Bars represent cognitive test-scores [SEM] for quintiles of insulin resistance (HOMA) in non diabetic 
participants (from lowest (Q1) to the highest (Q5) levels of insulin resistance), and for participants with 
a history of diabetes (DM). Linear mixed models were used, adjusted for age, sex and level of education; 
Estimates are based on the maximum number of participants available per cognitive test; MMSE (n = 
3452), LDST (n = 3401 ), Stroop test trial 3 (n = 3360), WFT (n = 3424). P-values reflect the trend over the 
quintiles of insulin resistance (HOMA), and the difference between participants without a history of 
diabetes (n = 3139) and participants with a history of diabetes (n = 313).
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insulin resistance and cognitive function that is shown in Figure 5, is in accordance with find-
ings on fasting glucose levels and cognitive function: in participants without a history of 
diabetes, rising insulin resistance was not associated with cognitive function. Similarly, there 
was no clear relation between levels of insulin resistance and change in cognitive function 
during follow-up (Figure 6).
Additional adjustment for systolic and diastolic blood pressure, HDL-cholesterol level and 
APOE ε4 carrier ship did not markedly change any of the associations linking fasting glucose / 
insulin resistance with measures of cognitive function / change. We additionally analyzed the 
relation between fasting glucose levels and cognitive function and decline in strata of BMI, 
to investigate possible effect modification. There were no differences seen in the association 
between fasting glucose levels and cognitive function in the different strata of BMI compared 
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 Figuur 6. 
Mini Mental State Examination Letter-Digit Substitution Task 
Stroop Test trial 3 Word Fluency Test 
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Figure 6. Insulin resistance (HOMA) and annual change in cognitive function in the Rotterdam Study.
Bars represent annual change in cognitive test-scores [SEM] for quintiles of insulin resistance (HOMA) in 
non diabetic participants (from lowest (Q1) to the highest (Q5) levels of insulin resistance (HOMA)), and 
for participants with a history of diabetes (DM). Linear mixed models were used, adjusted for age, sex and 
level of education; Estimates are based on the maximum number of participants available per cognitive 
test; MMSE (n = 2584), LDST(n = 2562), Stroop test trial 3 (n = 2541), WFT (n = 2567 ). P-values reflect the 
trend over the quintiles of insulin resistance (HOMA), and the difference between participants without a 
history of diabetes (n = 2379) and participants with a history of diabetes (n = 205).
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to the total samples. Interaction-terms of BMI and fasting glucose levels were added to the 
linear mixed models, but were not significant.
All analyses were based on the maximum amount of cognitive data that were available 
for the different cognitive tests that were assessed in both cohorts. When we restricted our 
analyses to those participants who had complete data available on all the cognitive tests in 
the neuropsychological test battery (PROSPER; (n = 4857), Rotterdam Study; (n = 3413)), the 
results did not change (data not shown).
comment
Our study shows that in two large independent prospective studies, higher levels of fasting 
glucose in absence of a history of diabetes mellitus are not associated with cognitive function 
or decline. Furthermore, there was no association between insulin resistance (HOMA index) 
and cognitive function and decline in people without a history of diabetes. Participants 
with a history of diabetes, however, did have clear evidence of worse cognitive function at 
baseline, and there was some evidence of an accelerated rate of decline in cognitive function 
during follow-up.
When we extended the diabetes group with “new diabetic” participants without a history 
of diabetes but who had a fasting glucose level ≥ 7.0 mmol/L, the already modest relation 
between fasting glucose levels and cognitive function in participants without diabetes 
became even less clear. Furthermore, the difference in cognitive function between this ex-
tended diabetes mellitus group and the non-diabetic participants was less apparent in these 
analyses. This supports the idea that there is no clear relation between fasting glucose levels 
and cognitive function in the absence of a history of diabetes mellitus, and that the “new dia-
betics” are on their way to become part of the group with a history of diabetes, with respect 
to cognitive function.
Together with diabetes or an impaired fasting glucose level, many other cardiovascular 
risk factors often co-occur in individual participants. The metabolic syndrome is seen as a 
clustering of a number of these risk factors (abdominal obesity, hypertriglyceridemia, low 
HDL-cholesterol, hypertension and hyperglycemia) and is the subject of an ongoing discus-
sion on the clinical use of the syndrome and its individual components in establishing the risk 
of cardiovascular disease and diabetes.30 Other studies have suggested a relation between 
the metabolic syndrome and the risk of cognitive impairment and dementia.31-33 In our study, 
the clustering of these factors of the metabolic syndrome with the fasting glucose levels we 
assessed could have influenced our results. However, the results from the analyses that we 
stratified for BMI, and additionally adjusted for several of these factors (systolic and diastolic 
blood pressure, HDL-cholesterol) did not differ from the analyses that were unadjusted for 
these covariates.
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We used fasting insulin levels that were available in almost the entire sample of the Rot-
terdam Study to calculate the HOMA index as a measure of insulin resistance to further 
investigate the relation between glucose metabolism and cognitive function. However, the 
relation between insulin resistance and cognitive function and decline showed similarities 
with the association between fasting glucose levels and cognitive function and decline: in 
participants without a history of diabetes, insulin resistance was not associated with cogni-
tive function or decline.
The strengths of this study consist of the prospective design, the large amount of par-
ticipants in both studies, and the dedicated neuropsychological test battery that was used 
in both samples. Furthermore, we had the possibility to study the variability of the fasting 
glucose levels during follow-up and to examine the appropriateness of using a single mea-
surement of fasting glucose level to assess the association between fasting glucose levels 
and cognitive function and decline. A large variation in fasting glucose levels over time could 
have disturbed our analyses through the phenomenon of “regression-to-the-mean”. However, 
the levels of fasting glucose during follow-up did not materially differ from the baseline or 3rd 
survey in both study samples. Therefore we decided to use the baseline or 3rd survey fasting 
glucose measurement in our analyses.
Some limitations need to be addressed. Participants who were present at baseline but 
dropped out of the study during follow-up were predominantly present in the group with 
a history of diabetes. They had worse cognitive function at baseline compared to the par-
ticipants that stayed in the study until the end of follow-up. This selective drop-out of par-
ticipants with relatively high levels of fasting glucose and concurrent low levels of cognitive 
function could have resulted in an underestimation of our estimates of cognitive decline for 
participants with a history of diabetes. We also recognize that some individuals with diabetes 
would have been missed because of lack of oral glucose tolerance testing (OGTT) – how-
ever, oral glucose tolerance testing on such a large number of individuals would have been 
onerous. More importantly, undiagnosed diabetes would be more prevalent in those in the 
higher quintiles for fasting glucose and would have biased the study towards an association 
of higher quintiles and cognitive decline, not the other way around. Thus, lack of OGTT does 
not negate our findings; rather it gives us added confidence that our observations are valid.
In conclusion, elevations in fasting glucose levels are not clearly associated with impaired 
cognitive function or with an accelerated rate of cognitive decline in participants without 
a history of diabetes. Furthermore, there was no clear relation between insulin resistance 
(HOMA index) and cognitive function and decline in participants without a history of diabe-
tes. These data suggest that cognitive decline accelerates strongly once diabetic but not with 
lesser degrees of dysglycaemia. As a result, preventing individuals at risk from developing 
diabetes through lifestyle changes, may also lead to large societal gains by preventing such 
individuals from undergoing accelerated cognitive decline.
45
A Prospective Analysis of Elevated Fasting Glucose Levels and Cognitive Function in Older People: Results from the PROSPER and Rotterdam Studies.
Ch
ap
te
r 3
.1
reFerences
 1. Ott A, Stolk RP, Van Harskamp F, Pols HAP, Hofman A, Breteler MMB. Diabetes mellitus and the risk 
of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
 2. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabetic 
Medicine 1999; 16: 93-112.
 3. Grodstein F, Wilson RS, Chen J, Manson JE. Type 2 diabetes and cognitive function in community-
dwelling elderly women. Diabetes Care 2001; 24: 1060-1065.
 4. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barret-Connor E, Krueger K. Diabetes, impaired 
fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 
658-663.
 5. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive 
impairment. Arch Neurol 2007; 64: 570-575.
 6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: 
a systematic review. Lancet Neurol 2006; 5: 64-74.
 7. Münch G, Schinzel R, Loske C, et al. Alzheimer’s disease-synergistic effects of glucose defecit, 
oxidative stress and advanced glycation endproducts. J Neural Transm 1998; 105: 439-461.
 8. Craft S. Insulin resistance syndrome and Alzheimer’s disease: Age- and obesity-related effects on 
memory, amyloid and inflammation. Neurobiology of Aging 2005; 26S: S65-S69.
 9. Lindahl B, Weinehall L, Asplund K, Hallmans G. Screening for impaired glucose tolerance. Diabetes 
Care 1999; 22: 1988-1992.
 10. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting 
glycaemia: the current status on definition and intervention. Diabetes Med 2002; 19: 708-723.
 11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert 
committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl 
1): S5-S20.
 12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report 
on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
 13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 
2005; 28 (Suppl 1): S37-S42.
 14. Dekker JM, Balkau B. Counterpoint: impaired fasting glucose: the case against the new American 
Diabetes Association guidelines. Diabetes Care 2006; 29:1173-1175.
 15. Fontbonne A, Ducimetière P, Berr C, Alpérovitch. Changes in cognitive abilities over a 4-year pe-
riod are unfavorably affected in elderly diabetic subjects. Results of the Epidemiology of Vascular 
Aging Study. Diabetes Care 2001; 24: 366-370.
 16. Kanaya AM, Barret-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose 
tolerance status in older adults. A 4-year prospective study of the Rancho Bernardo Study Cohort. 
Arch Intern Med 2004; 164: 1327-1333.
 17. Fuh JL, Wang SJ, Hwu CM, Lu SR. Glucose tolerance status and cognitive impairment in early 
middle-aged women. Diabetic Med 2007; 24: 788-791.
 18. Abbatecola AM, Paolisso G, Lamponi M, et al. Insulin resistance and executive dysfunction in 
older persons. J Am Geriatr Soc 2004; 52: 1713-1718.
 19. Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and 
implications for treatment. Current Alzheimer Research 2007; 4: 147-152.
 20. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a PROspective Study of Paravastatin in the 
Elderly at Risk (PROSPER). Am J Cardiol 1999; 84: 1192-1197.
Chapter 3.1
46
 21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease 
(PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-1630.
 22. Hofman A, Breteler MMB, van Duijn CM, et al. The Rotterdam Study: objectives and design update. 
Eur J Epidemiol 2007;22:819-829.
 23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-198.
 24. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment, 4th ed. New York, NY:Oxford 
University Press, 2004.
 25. Golden CJ. Identification of brain disorders by the stroop color and word test. J Clin Psychol 1976; 
32:654-658.
 26. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44(4):609-
614.
 27. Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: the PROS-
PER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 
2002;73:385-389.
 28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model 
assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985; 28: 412-419.
 29. Bonara E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose 
clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees 
of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
 30. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascu-
lar disease and diabetes? Outcome data from two prospective studies. Lancet 2008 (in press).
 31. Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer 
disease. Neurology 2006; 67: 843-847.
 32. The metabolic syndrome, inflammation, and risk of cognitive decline. Yaffe K, Kanaya A, Lindquist 
K, et al. JAMA; 292: 2237-2242.
 33. Kalmijn S, Foley FL, Burchfiel CM, et al. Metabolic cardiovascular syndrome and risk of dementia 
in Japanese-American elderly men: The Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol 
2000; 20: 2255-2260.
47
3.2
Genetic Influence on Insulin/IGF‑1 
Signaling and Cognitive Function
ABstrAct
Background: An accumulating body of evidence suggests the involvement of an evolutionary 
conserved insulin/insulin-like growth factor-1 (IGF-1) signaling (IIS) pathway in the regulation 
of the life and health span in nematodes, flies, rodents, and humans.
methods: We studied the association between insulin/IGF-1 signaling and cognitive func-
tion among 1015 participants, 85 years old or older, of the population-based Leiden 85-Plus 
Study. A composite IIS6 score, based on expected effects (increased or decreased signaling) 
of selected variants in the IIS pathway, was calculated to estimate IIS pathway activity. Cog-
nitive function was assessed at baseline and annually during a 5-year follow-up, using the 
Mini-Mental State Examination (MMSE).
results: In women, but not in men, lower IIS6 scores (indicating decreased signaling) were 
associated with a lower risk of cognitive impairment (MMSE score ≤ 18) (p trend = .010). The 
IIS6 score was not associated with change in cognitive function.
conclusion: In addition to old age survival, genetically reduced IIS seems to be beneficial for 
cognitive function in women.
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introdUction
The involvement of the evolutionary conserved insulin/ insulin-like growth factor-1 (IGF-1) 
signaling (IIS) pathway in the hormonal regulation of aging has been shown in a number 
of model organisms like nematodes, flies, and rodents.1-8 Genetic variation that causes a 
reduced IIS activation was associated with an increased life span in these organisms, with a 
stronger effect seen in the female sex.6,9-11 In accordance with these data on model organisms, 
we previously showed an association between a genetically reduced IIS pathway and better 
survival in elderly women.12
Moreover, in model organisms, the IIS pathway has not only been implicated in the deter-
mination of life span but also in that of health span. At old age, there is a high prevalence 
of cognitive impairment, which for many is one of the most frightening prospects of old 
age. An accumulating body of evidence suggests the involvement of insulin and IGF-1 in the 
development of cognitive impairment.13-15 Suggested biological mechanisms that underlie 
this relationship are inhibition of the amyloid β breakdown (through the insulin-degrading 
enzyme) and the involvement of insulin and IGF-1 in τ phosphorylation.14,16,17 In humans, it is 
yet to be elucidated how the evolutionary conserved IIS pathway, which has been shown to 
be associated with better survival in old age, is related to cognitive function and decline.
Therefore, we studied the relationship between genetic variation in IIS pathway activation 
and cognitive function and decline in a prospective, population-based study among 1015 
participants of the Leiden 85-Plus Study.
metHods
Population
The Leiden 85-Plus Study is a prospective, population-based cohort study that consists of 
two cohorts of inhabitants of Leiden, The Netherlands.18,19 For cohort ’87, 977 inhabitants of 
Leiden, 85 years old or older, were enrolled between 1987 and 1989, and cognitive function 
was assessed at baseline. For cohort ’97, 599 inhabitants of Leiden, 85 years old, were enrolled 
between 1997 and 1999. Cognitive function was assessed at baseline and annually during 
home visits, from age 85 until age 90 years. Of the 1576 participants in the two cohorts of 
the Leiden 85-Plus Study, DNA was available for 1245 participants, and IIS scores could be 
calculated for 1037 participants.12 Twenty-two participants did not have cognitive data avail-
able at baseline, resulting in a study sample of 1015 participants.
IIS Score
To determine the genetic variation that influences IIS, we selected six polymorphisms in 
five genes from the IIS pathway (Growth Hormone Releasing Hormone Receptor (GHRHR); 
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Growth Hormone 1 (GH1); Insulin-like Growth Factor 1 (IGF1); Insulin (INS); and Insulin Re-
ceptor Substrate 1 (IRS1)) based on previous reports of their effects on gene expression or 
protein function. As the effect sizes of the six selected IIS polymorphisms were unknown, 
these were assumed to be equal, and a simple additive model (hereafter referred to as IIS6 
score) was used to test for combined effects of the selected polymorphisms. Per individual, 
we calculated a composite IIS6 score by assessing a value of –1 for carriership of each variant 
predicted to cause reduced IIS activity (GHRHR rs4988496, GH1 rs2665802, IGF-1 CA repeat, 
INS Variable Number Tandem Repeats (VNTR), IRS1 rs1801278), and a value of +1 for carrier-
ship of the variant predicted to cause increased IIS activity (IGF1 CT repeat). In total, the IIS6 
score could be calculated for 1037 of the 1245 participants for whom DNA was available. 
Because of the limited number of participants (n = 3) with an IIS6 score of –5, we included 
these participants in the IIS6 score –4 category. Likewise, the participants in the IIS6 score +1 
category (n = 6) were included in the IIS6 score 0 category. A more detailed description of the 
selected polymorphisms and assessment of the IIS6 score have been published elsewhere.12
Cognitive Function
Cognitive function was assessed with the Mini-Mental State Examination (MMSE),20 and was 
available for 1015 participants of both cohorts at baseline. The MMSE is a measure of global 
cognitive function and ranges from 0 to 30 points, with lower scores indicating worse cognitive 
function. Although the MMSE is a widely used test that was developed as a screening instru-
ment for dementia and is a reliable measure of global cognitive function, it might lack reliabil-
ity and validity in persons with severe cognitive impairment.21 Therefore, we dichotomized 
the cognitive test scores and defined cognitive impairment as an MMSE-score ≤ 18 points. 
Additionally, 455 of the 511 participants of cohort ’97 underwent at least one measurement 
of the MMSE during follow-up, resulting in a study sample of 455 participants available for the 
longitudinal analyses. Annual change in cognitive function was assessed by comparing test 
scores at baseline with those at the last available follow-up visit. Annual change in cognitive 
function was calculated as the difference between test score at baseline and test score at the 
last available year of follow-up, divided by the length of follow-up (1–5 years).
Statistical Analyses
The relationship between the IIS6 score and the risk of cognitive impairment was assessed 
with logistic regression models.
The relationship between the IIS6 score and the annual change in cognitive function dur-
ing follow-up was assessed with analyses of covariance, with the annual change in cognitive 
function as the dependent variable, and the IIS6 score as the grouping variable. To assess 
the association between the 1-unit increase in IIS6 score and the annual change in cognitive 
function, we used linear regression models with the annual change in MMSE score as the 
dependent variable and the IIS6 score as the independent variable.
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All analyses were adjusted for age and carried out using the SPSS statistical package (re-
lease 12.0.1; SPSS, Inc., Chicago, IL).
resUlts
Table 1 shows the baseline characteristics of the study participants. The mean age of the 1015 
participants from the combined cohorts of the Leiden 85-Plus Study was 87.4 years, and 68% 
were women. Mean MMSE score at baseline was 23.9 points and ranged from 0 to 30 points.
Table 2 shows the sex-specific relationship between the composite IIS6 score and the risk 
of cognitive impairment, adjusted for age. A higher IIS6 score was associated with a higher 
table 1. Baseline Characteristics
Characteristic Combined Cohorts Cohort ‘87 Cohort ‘97
Number 1015 504 511
Age, y (SD) 87.4 (3.1) 89.8 (2.9) 85 (0)
No. of women (%) 68 69 66
MMSE-score, points (SD) 23.9 (6.4) 23.9 (6.4) 23.8 (6.5)
IIS6-score, points (IQR) –2 (–3 to –1) –2 (–3 to –1) –2 (–2 to –1)
Note: Data are presented as mean (standard deviation [SD]), percentage, or median (interquartile range 
[IQR]). MMSE, Mini-Mental State Examination, IIS6 score, insulin/insulin-like growth factor-1 signaling 
score.
table 2. Association Between Insulin/IGF-1 Signaling Score and the Risk of Cognitive Impairment in the 
Leiden 85-Plus Study
Women Men
IIS6 Score n MMSE 
Score
OR (95% CI) ptrend n MMSE 
Score
OR (95% CI) ptrend
–4 and –5 33 24.6 (1.2) 1 (Ref ) .010 13 22.8 (1.5) 1 (Ref ) .329
–3 139 24.0 (0.6) 0.80 (0.29-2.17) 73 24.3 (0.6) 0.55 (0.13-2.33)
–2 259 23.8 (0.4) 1.09 (0.42-2.78) 120 25.1 (0.5) 0.32 (0.08-1.35)
–1 193 22.5 (0.5) 1.65 (0.64-4.24) 89 25.7 (0.6) 0.30 (0.07-1.35)
0 and +1 65 22.3 (0.8) 1.61 (0.56-4.57) 31 24.0 (1.0) 0.56 (0.11-2.87)
Per IIS6 
score
689 1.28 (1.06-1.53) 326 0.85 (0.60-1.19)
Notes: Insulin/insulin-like growth factor-1 (IGF-1) signaling (IIS)6 scores were calculated for each 
participant by assigning a score of +1 for carriership of a gene variant causing increased signaling and a 
score of –1 for carriership of a gene variant causing decreased signaling. Because of the limited number of 
participants with an IIS6 score of –5 (n = 3) or an IIS6 score of +1 (n = 6), we combined these, respectively, 
with the IIS6 score –4 and IIS6 score 0 categories. Mini-Mental State Examination (MMSE) scores 
(standard error [SE]) are presented per IIS6 score category. Odds ratios (OR) represent the risk of cognitive 
impairment per IIS6 score category. In women, 146 cases of cognitive impairment were present, in men, 
38 cases were present. Values of ptrend represent the linear trend for the risk of cognitive impairment per 
increase in IIS6 score. All analyses were adjusted for age. CI, confidence interval.
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risk of cognitive impairment, but only for women (odds ratio [95% confidence interval] per 
1-unit increase in IIS6 score was 1.28 [1.06-1.53], p = .010). In men, a higher IIS6 score was, if 
anything, associated with a lower risk of cognitive impairment (odds ratio [95% confidence 
interval] per 1-unit increase in IIS6 score was 0.85 [0.60-1.19], p = .329).
The longitudinal analyses, which were performed of 455 participants of cohort ’97 only, 
showed no clear relationship between the IIS6 score and the annual change in cognitive 
function during follow-up. In both women (annual change in MMSE score [standard error 
{SE}]) per 1-unit increase in IIS6 score was –0.06 [0.12] points, p = .612) and men (annual 
change in MMSE-score [SE] per 1-unit increase in IIS6 score was –0.16 [0.15] points, p = .311) 
a higher IIS6 score was not associated with an accelerated or decelerated rate of decline in 
cognitive function during follow-up.
discUssion
Our study showed that, in humans, a genetically reduced IIS pathway was associated with 
a lower risk of cognitive impairment in women, but not in men. There was no association 
between the IIS pathway and a change in cognitive function over time.
Together with our previous finding that showed an association between a genetically 
reduced IIS pathway with improved old age survival in women,12 our current findings are in 
accordance with the available data from model organisms that showed favorable effects of 
genetically induced lower IIS activity on both life span and health span. In model organisms, 
such as Caenorhabditis elegans, down-regulation of the IIS pathway occurs in response to 
adverse environmental conditions, such as food shortage. Its main function is to coordinately 
adapt various aspects of the worm’s physiology, so that priorities are changed from growth 
and reproduction to mere survival until conditions become more favorable. In C. elegans, 
environmentally, as well as genetically induced down-regulation of the IIS pathway can 
dramatically increase life span, with concurrent maintenance of functional abilities.22 Fur-
thermore, it was shown that the mutations in the IIS pathway are associated with associative 
learning behavior in C. elegans.23
At first glance, the beneficial effects of genetically induced down-regulation of the IIS 
pathway seem to conflict with the available data on the association of IGF-1 serum levels with 
the human health span. In humans, the activity of the hypothalamic–growth hormone (GH)–
IGF-1 axis declines with age, and several aspects of functional decline, including cognitive 
decline, have been attributed to the somatopause. In several studies, higher levels of total 
circulating IGF-1 were associated with better cognitive function and less cognitive decline 
in elderly persons,24,25 although in at least one study, free IGF-I levels were not associated 
with cognitive decline.25 The a priori prediction based on the genetic data from long-lived 
worms would have predicted an association between low serum IGF-1 levels (instead of high 
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levels) and improved survival and better maintenance of functional abilities.22 Recently, a 
similar paradox was observed in mice: decreased IGF-1 levels are not only a key feature of 
the serum profile of long-lived mice, such as calorically restricted wild-type mice, but also of 
mice that are short-lived due to mutations in DNA repair.26,27 The picture that now emerges 
is that down-regulation of IIS is an ancient survival response that can occur both in response 
to sudden external stresses (such as food shortage) as well as in response to chronic internal 
stresses (such as the accumulation of damage with aging).28 Likewise, in humans, the decline 
in GH/IGF-1 levels with age may be an adaptive response aimed to prolong survival. Accord-
ing to this hypothesis, higher serum IGF-1 levels in old age might be indicative of a lower 
degree of (age-associated) accumulated damage.
The observed sex-specific involvement of IIS pathway activity in the development of cogni-
tive impairment that is presented here is supported by previous findings. In the first discovered 
long-lived C. elegans mutant that mapped to the IIS pathway, both male and hermaphrodite 
worms were shown to be affected by age.1 Moreover, in female but not in male rats, height-
ened cognition, in addition to increased motor activity and reproductive shutdown, was 
observed as an important aspect of the survival response to caloric restriction.29 Improved 
learning and memory may play important roles in the success of seeking food elsewhere, 
which is especially important for the female sex, as females must obtain sufficient energy to 
support the survival and development of their offspring as well as themselves. The possible, 
not mutually exclusive, mechanisms by which reduced IIS pathway activity may contribute 
to heightened cognition in elderly females, include increased stress resistance and reduced 
amyloid β–induced autophagosome accumulation. Recent data obtained in a C. elegans 
model suggest that reduced IIS activity promotes the maturation of autophagosomes into 
degradative autolysosomes, whereas amyloid β impairs this process.30 Another study showed 
the involvement of IIS pathway mediation in the aggregation-mediated amyloid-β toxicity in 
C. elegans.31
The observed association between a lower IIS6 score and better cognitive function was not 
seen in the longitudinal analyses. A lower IIS6 score was not associated with an accelerated 
or decelerated rate of decline in cognitive function during follow-up. A possible explana-
tion could be that there were only longitudinal data on cognitive function available for the 
participants of cohort ’97, which reduced our sample size and concurrently the statistical 
power of our analyses. Furthermore, it has been suggested that in situations with substantial 
dropout during follow-up, cross-sectional analyses may provide the better estimates.32,33 
Therefore, cross-sectional estimates might have been the preferred choice here to study 
the relationship between IIS and cognition as we were testing the consequence of genetic 
variants that have accumulated over a lifetime. Alternatively, genetically determined lifelong 
lower IIS activity may mainly have an effect on the onset of cognitive decline (postponing it 
to a later age) and not on the rate of the decline.
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In conclusion, we showed that genetically reduced IIS seems to be beneficial for cognitive 
function in women but not in men. These results are in line with our previous findings that 
showed associations between reduced IIS signaling and increased longevity in women, and 
further indicates the involvement of the IIS pathway in the regulation of health span.
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4.1
The Effect of Age on the Association of Blood 
Pressure with Cognitive Function Later in Life
ABstrAct
Background: High blood pressure at middle-age relates to worse cognitive function later 
in life. It is unclear whether this relation is similar in old age. Therefore we examined the 
relationship between baseline blood pressure and cognitive function later in life across age 
groups.
methods: We used data from two independent population-based cohort studies: the Rot-
terdam Study (3078 participants, initial age 55-84 years, mean follow up 11 years) and the 
Leiden 85-plus Study (276 participants, initial age 85 years, follow-up 5 years). Systolic and 
diastolic blood pressure were measured at baseline, cognitive function was assessed at the 
end of follow-up with a dedicated neuropsychological test battery. The association between 
baseline blood pressure levels and cognitive function later in life was assessed in 10-year age 
groups in the Rotterdam Study and in the 85-year olds of the Leiden 85-plus Study.
results: In the youngest participants (<65 years), systolic and diastolic blood pressure were 
not associated with cognitive function 11 years later. For persons aged 65-74 years, higher 
baseline systolic and diastolic blood pressure were related to worse cognitive function 11 
years later. In contrast, in older age (over 75 years) higher systolic and diastolic blood pres-
sure were related to a better cognitive function at the end of follow-up This effect appeared 
strongest in the highest age group (85 years).
conclusions: High blood pressure increases the risk of cognitive impairment up to 75 years 
but is associated with better cognitive function thereafter. Age-specific guidelines for blood 
pressure management are needed, as the current directive that ’lower is better’ may not ap-
ply to blood pressure levels in the very old.
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introdUction
Data on the relation between blood pressure and cognitive function are not consistent, not-
withstanding a large number of studies that investigated the relation between blood pressure 
and cognitive function.1 Most studies report that higher blood pressure levels at middle-age 
relate to cognitive impairment later in life.2-5 However, results on the relation of higher blood 
pressure in older age and later cognitive function are conflicting. Some studies showed a 
negative effect of higher blood pressure on cognitive function,6,7 whereas others did not.8,9 
These findings may suggest that age influences the relation between blood pressure and 
cognitive function. When correct, this might have consequences for blood pressure man-
agement, especially in the very old. Earlier evidence for beneficial effects of blood pressure 
lowering on cognitive function in older people,10 could not be replicated in recent studies,11 
despite the fact that stroke risk was significantly reduced in those studies. Therefore, we ex-
amined the effect of age on the relationship between baseline blood pressure and cognitive 
function later in life over a wide range of age groups in two prospective population-based 
studies, i.e. the Rotterdam Study and the Leiden 85-plus Study. We hypothesized that the 
relationship between blood pressure and cognitive function changes with age. Whereas high 
blood pressure is a risk factor for cognitive impairment at middle-age, it might also have 
beneficial effects in old age.
metHods
Populations
The Rotterdam Study is a large prospective population-based cohort study that was con-
ducted among all inhabitants aged 55 years and over of Ommoord, a district of Rotterdam, 
The Netherlands.12 The medical ethics committee of the Erasmus University of Rotterdam 
approved the study, and informed consent was obtained from all participants. Of 10,275 
eligible subjects, 7983 individuals (78%) participated in the baseline examinations between 
1990-1993 (mean age 71±25, range 55-106). All participants were interviewed at home, and 
visited the research center for further examinations. At the 4th survey (2002-2004) cognitive 
function was extensively assessed by use of a dedicated neuropsychological test battery.
The Leiden 85-plus Study is a prospective population-based cohort study of 85-year-old in-
habitants of Leiden, The Netherlands. The medical ethics committee of the Leiden University 
Medical Centre approved the study, and informed consent was obtained from all participants. 
Between September 1997 and September 1999, all inhabitants of Leiden born between 1912 
and 1914 (n=705) were contacted within a month after their 85th birthday. A total of 599 
individuals (87%) agreed to participate. From age 85 till 90 years, annual neuropsychological 
tests were performed during home visits.
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Study sample
In the Rotterdam Study, the sample for this study was restricted to participants aged 55-85 
years and with blood pressure measurements at baseline (n=6502) due to the limited number 
of participants aged 85 years and over with follow-up examinations 11 years later (n=4). Of 
these 6502 participants, 3424 individuals (56%) did not participate in the 4th survey; 63% 
had died, 30% refused the in person examination or were too ill to visit the research center, 
and 7% could not be contacted. The proportion of participants who did not participate in 
the 4th survey increased with age from 31% for age group 55-64 years to 54% for age group 
65-74 years and 88% for age group 75-84 years. The study sample therefore consisted of 3078 
participants with both baseline blood pressure measurements and cognitive measurements 
11 years later.
In the Leiden 85-plus Study, blood pressure was measured in 572 participants at age 85 
years. Of these 572 participants, 276 participants underwent neuropsychological testing 5 
years later at age 90 years. Of the remaining 296 individuals (52%) who did not participate at 
age 90 years, 88% had died, and 12% refused to participate.
Blood pressure
In both study samples, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
measured twice at baseline with a sphygmomanometer, after 5 minutes of seated rest. The 
averages of two measurements were used in the analyses. In the Rotterdam Study, the two 
measurements were separated by a count of the pulse rate. In the Leiden 85-plus Study the 
two measurements were two weeks apart.
Cognitive function
Global cognitive function was measured in both cohorts with the Mini-Mental State Examina-
tion (MMSE).13 We used a serial 7’s question only, not the WORLD-backward version. In addi-
tion, a dedicated neuropsychological test battery was used to assess executive function and 
memory. Executive function was assessed with the abbreviated Stroop test part 314 and the 
Letter Digit Substitution Task (LDST)15 in both cohorts and with the Word Fluency Test (WFT)16 
in the Rotterdam Study only. Memory was assessed with the 15-Word Learning Test (15-WLT) 
immediate and delayed recall,17 in the Rotterdam Study, and with the 12-Picture Learning 
Test (12-PLT) immediate and delayed recall,18 in the Leiden 85-plus Study. Dutch translated 
and validated versions were used for all neuropsychological tests.
The MMSE-score was used as a measure of global cognitive function and ranges from 0 to 
30 points, with lower scores indicating worse cognitive function. In the Leiden 85-plus Study, 
executive function and memory were not assessed in participants with a MMSE-score of 18 
points or lower (n = 74) as it was assumed that the tests lack reliability and validity in subjects 
with severe cognitive impairment. These participants were assigned to the lowest quartile of 
the distribution to reflect their impaired state of cognitive function.
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Additional measurements
In both study populations, education was measured at baseline and dichotomized into 
primary education or less, and more than primary education. Antihypertensive drug-use was 
determined at baseline during the home interview (Rotterdam Study) or through pharmacy 
records (Leiden 85-plus). Additionally, smoking status, alcohol intake, history of stroke, his-
tory of diabetes and history of cardiovascular disease were assessed at baseline.
Statistical analysis
The association between baseline blood pressure and cognitive function later in life was 
examined using linear regression models, with blood pressure as independent and cognitive 
test score as dependent variable. All analyses were adjusted for age (Rotterdam Study only), 
sex, and education level. Additional adjustments were made for the use of antihypertensive 
drugs, smoking status, alcohol intake, history of stroke, history of diabetes and history of 
cardiovascular disease. Analyses were carried out using the SPSS statistical package (release 
11.1; SPSS inc., Chicago, Illinois).
resUlts
Table 1 shows the baseline characteristics of participants who did and did not undergo cog-
nitive testing at the follow-up examination for both cohorts. In both studies, the percentage 
of women was higher and their proportion increased with age. The level of education was 
lower in older age, i.e. among those who originate from earlier birth cohorts. Average SBP 
increased while DBP decreased with age. Among the oldest old however, DBP was highest. 
The percentage of participants with a history of stroke, diabetes mellitus, or cardiovascular 
disease increased with age, together with the use of antihypertensive treatment.
In the Rotterdam Study, participants without cognitive assessment at follow-up were older, 
less educated, had higher SBP and DBP, and a worse cognitive function at baseline compared 
to the participants included in the analyses. This was seen similarly for all age groups from 55 
to 85 years. In the oldest old (Leiden 85-plus Study), the participants who did not undergo 
cognitive testing at the follow-up examination had lower SBP and DBP, and concurrent worse 
cognitive function at baseline compared to the participants included in the analyses. In both 
samples, the participants who were not included in the analyses more often had a history of 
stroke, diabetes mellitus, or cardiovascular disease compared to the participants in the study 
samples.
Figure 1 shows the effect of age on the association between baseline blood pressure and 
cognitive function later in life. Individuals up to 65 years of age showed in general little 
decline in cognitive function over the 11 year follow-up period, and neither baseline SBP 
nor DBP were related to cognitive function 11 years later. In individuals aged 65-74 years, 
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higher SBP and DBP at baseline were related to worse cognitive function 11 years later. With 
increasing baseline age, the effect of blood pressure on cognitive function seemed to invert: 
In individuals over 75 years of age, higher SBP and DBP at baseline were related to a better 
cognitive function 11 years later, although in the Rotterdam Study the number of people 
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Figure 1. The effect of age on the association of baseline blood pressure and cognitive function later in 
life.
Symbols represent the mean standardized cognitive test scores and 95% confidence intervals per 10 
mmHg increase in systolic (A) and diastolic (B) blood pressure. For graphical reasons, the estimates for 
the Stroop test were inversed as a higher Stroop score reflects worse cognitive function. Analyses were 
adjusted for age (Rotterdam Study only), sex and level of education.
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in this age group was rather small and consequently results not significant for the majority 
of tests. This effect was however even stronger in the highest age group (85 years, subjects 
from the Leiden 85-plus Study) where higher SBP and DBP were related to a better cognitive 
function 5 years later. The shift from risk to benefit of high blood pressure from age 65 to 85 
years and over was observed for all neuropsychological tests (Figure 1).
Additional adjustments
Additional adjustments for the use of antihypertensive drugs, smoking status, alcohol intake, 
history of stroke, history of diabetes or history of cardiovascular disease did not markedly 
change any of these results (data not shown).
discUssion
Our data show that age has an important effect on the relation between actual blood pressure 
and cognitive function later in life. In participants aged up to 74 years, both higher SBP and 
DBP were, if anything, associated with worse cognitive function 11 years later. This relation 
reversed in older participants, in whom higher SBP and DBP at baseline were associated with 
better cognitive function later in life.
The detrimental effect of higher blood pressure levels on cognitive performance in the 
middle-aged is well established,2-5 and the results from our analyses in the 65-74 year age 
group in the Rotterdam Study sample were consistent with these previous findings. The 
mechanisms behind this association may involve atherosclerotic changes in large and hyaline 
degeneration in small cerebral vessels, ischemic brain lesions and disturbances in endothelial 
or brain cell permeability.1-5 However, in the oldest-old participants in the Rotterdam Study 
high blood pressure at baseline was, if anything, related to better cognitive function later in 
life, and when we replicated our analyses in the 85 year old participants of the Leiden 85-plus 
Study sample we found similar results.
In our study, participants with a relatively low blood pressure and good cognitive function 
at baseline were more likely to be included in the study sample than participants with higher 
blood pressure and worse cognitive function at baseline. One might expect that this selective 
attrition could have influenced our results, especially in the oldest age group of the Rot-
terdam Study where a large proportion of the participants who were present at baseline were 
not available at follow-up anymore. Although a large proportion of participants in especially 
the oldest age group in the Rotterdam Study were not included in the study sample due 
to missing data, the selective drop out was seen across all age groups from 55 to 85 years. 
Furthermore, the participants in the oldest age group (Leiden 85-plus Study) for which we 
do not have follow-up examinations had predominantly lower blood pressure levels and 
worse cognitive function when compared to those who are included in the analyses. When 
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taken together, it is unlikely that selective attrition in itself can explain for our results, and 
this concurs with previous findings that high blood pressure is not a risk factor for mortality 
in the oldest old.19,20
The previous studies that associated higher blood pressure in middle-age with worse 
cognitive function later in life,2-5 suggested that antihypertensive treatment might prevent or 
delay the onset of impaired cognitive function. However, data from randomized clinical trials 
on the beneficial effects of antihypertensive treatment on cognitive function are not consis-
tent.7,10,21-23 From these earlier studies, only the Syst-Eur trial10 showed benefit that could not 
be replicated in the HYVET-study.11 This large, double-blind, placebo-controlled trial included 
3336 participants aged 80 years or over and showed that antihypertensive treatment did 
not reduce incidence of dementia.11 Although this result could have been affected by the 
relatively short follow-up, owing to the early termination of the trial, the alternative explana-
tion is that there is no clear benefit in correspondence with the observational data presented 
here. Alternatively, the use of the relatively insensitive Mini-Mental State Examination as an 
outcome measure for cognitive impairment or decline could also have contributed to the in-
consistent findings in clinical trials. Another explanation is that the oldest old among whom 
impaired cognitive function is most prevalent were underrepresented in these studies.
It is tempting to speculate why blood pressure lowering is consistently associated with a 
lower risk of stroke whereas this benefit is not reflected in a consistent preservation of cogni-
tive function. Although counter intuitive, the aggregated data from the observational and 
experimental studies suggest that in the oldest old a higher blood pressure may have also 
have a benefit with respect to cognitive function, possibly through the necessity to maintain 
adequate cerebral perfusion.24-26 Cerebral perfusion is tightly regulated over a wide range of 
blood pressures by local regulation of cerebral blood flow.27 This autoregulation of cerebral 
blood flow is mediated by a combination of myogenic and neurogenic mechanisms.28 With 
increasing age, basal cerebral blood flow decreases, possibly caused by impaired cerebral 
autoregulation through atherosclerosis or endothelial dysfunction.29,30 In the oldest old, a 
higher blood pressure may therefore be required to prevent cerebral hypoperfusion and 
preserve cognitive function. These individuals with increased risk of morbidity and mortality 
are present in the population based prospective studies but are less likely to be included 
in the randomized clinical trials. Participants of the HYVET-study,11 who were randomized 
to placebo suffer a mortality risk less than half in comparison with the general population 
indicating the recruitment of relative healthy people into the trial.
Our study had several strengths. Data on blood pressure and cognitive function were avail-
able from two independent Dutch prospective population-based studies. These two cohorts 
are complementary and allowed us to examine the association between blood pressure level 
and cognitive function from age 55 years onwards. The dedicated neuropsychological test 
batteries that were used in both studies were comparable and assessed several cognitive 
domains, including global cognitive function, executive function, and memory. Some of the 
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participants in the oldest age group (Leiden 85-plus Study) could not undergo all the cogni-
tive tests that were available, because of their severely impaired cognitive status (MMSE-score 
≤ 18). Rather then excluding these persons from the analyses, we used the information on the 
cognitive status of these participants that was available (MMSE-score) to infer their scores on 
the other cognitive tests.
There were also some limitations. The associations of blood pressure and cognitive func-
tion were based on the assessment of blood pressure at baseline and the measurement of 
cognitive function 11 years (Rotterdam Study) or 5 years (Leiden 85-plus Study) later. The 
difference in follow-up length between the two study samples warrants some caution in the 
comparison and interpretation of the results, as the Rotterdam Study results are based on 
11 years of follow-up compared to 5 years of follow-up in the Leiden 85-plus Study. Despite 
the relatively long follow-up periods, extension of these periods may have revealed even 
stronger associations between baseline blood pressure and cognitive function later in life, 
as the effect of blood pressure on cognitive function is thought to be long-term.1 This may 
especially play a role up to age 65 years where the follow-up period may just have been too 
short. However, a longer follow-up, especially in older age, would also lead to a further drop 
out of participants and consequently to a limited statistical power.
conclUsion
In conclusion, this study shows that the relation between baseline blood pressure levels and 
cognitive function later in life differs across age groups. High blood pressure is a risk factor for 
cognitive impairment, especially up to age 75 years but may also help to preserve cognitive 
function in the oldest old as perfusion pressure is maintained. Further elucidation of risks and 
benefits of blood pressure lowering therapy in the oldest old have to be determined.
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4.2
Systemic Markers of Inflammation 
and Cognitive Decline in Old Age
ABstrAct
Background: Several lines of investigation suggest that inflammation is involved in the 
pathogenesis of dementia. However, the role of inflammatory markers in the early stages 
of the disease process, where there is cognitive decline but no full-blown clinical dementia 
syndrome is unclear. Therefore we investigated whether higher circulating levels of C-reactive 
protein (CRP), interleukin-6 (IL-6), and α1-antichymotrypsin (ACT) are associated with worse 
cognitive function and decline in old age.
methods: We used data from two independent population-based cohort studies: The Rotter-
dam Study (3874 individuals, mean age 72, mean follow-up 4.6 years) and the Leiden 85-plus 
Study (491 individuals, all aged 85, maximal follow-up 5 years).
In both studies inflammatory markers were measured at baseline, and global cognition, 
executive function and memory were assessed using a dedicated neuropsychological test 
battery.
results: In the Rotterdam Study, higher levels of CRP and IL-6 were cross-sectionally associ-
ated with worse global cognition and executive function (p<0.05). ACT was not associated 
with cognitive function. In the Leiden 85-plus Study estimates were similar for CRP, though 
not statistically significant. In the longitudinal analysis, higher IL-6 levels were related to a 
steeper annual decline in memory function in the Leiden 85-plus Study (p<0.05). The effect 
of higher IL-6 levels on global and memory function decline was stronger in APOE-ε4 carriers 
than in non APOE-ε4 carriers (p-interaction 0.011 respectively 0.048). In the Rotterdam Study, 
higher IL-6 levels were related to a steeper annual decline in global cognition in APOE-ε4 
carriers only.
conclusion: Systemic markers of inflammation are only moderately associated with cogni-
tive function and decline, and tend to be stronger in carriers of the APOE-ε4 allele. Systemic 
markers of inflammation are not suitable for risk stratification.
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introdUction
Several lines of investigation suggest that inflammation is involved in the pathogenesis of 
dementia. Animal models expressing high levels of pro-inflammatory cytokines in the brain 
suffer from neurodegeneration,1 whereas upregulation of pro-inflammatory cytokines in 
tissue cultures leads to microglial activation and neuronal damage.2 Furthermore, markers of 
inflammation are found in and around condense plaques in the brain,3 and several population-
based studies show an association of plasma levels of inflammatory markers with the risk of 
dementia.4,5 However, dementia develops over a long pre-clinical period, and its association 
with inflammatory markers may reflect a consequence of the disease process, rather than 
a causal association. In addition, elderly individuals with cognitive dysfunction often have 
co-morbidities, which might underlie their elevated inflammatory markers. Therefore, it is 
important to investigate the role of inflammatory markers in the early stages of the disease 
process, where there is cognitive decline but no full-blown clinical dementia syndrome yet.
Several studies have reported an association of inflammatory markers with cognitive 
decline. However, these studies were relatively small,6-8 had a relatively short follow-up,6,9 in-
cluded only one marker of inflammation,7 and typically did not include substantial numbers 
of individuals aged 80 years or over. Moreover, these studies, except for one,6 did not account 
for the possible interrelationships between inflammatory markers, atherosclerosis, and 
cognitive decline. Many elderly individuals have atherosclerosis, which is a strong risk factor 
for the development of cognitive decline,10 and which is strongly related to inflammatory 
markers such as C-reactive protein (CRP).11 Therefore, the observed associations between 
inflammatory markers and cognitive decline may be non-specific, i.e., due to the presence 
of atherosclerosis.
In view of these considerations, we tested the hypothesis that higher levels of the inflam-
matory markers CRP, interleukin-6 (IL-6) and α1-antichymotrypsin (ACT) are associated with 
cognitive decline and investigated whether this association is mediated by atherosclerosis, 
in two large prospective population-based studies: the Rotterdam Study and the Leiden 85-
plus Study. Both studies used a dedicated neuropsychological test battery to assess cognitive 
decline. As the APOE ε4 allele is an important risk factor for cognitive decline,12,13 which may 
assorts its effects via inflammatory mechanisms, we also investigated the effect of APOE ε4 
carriership on the association between inflammatory markers and cognitive decline.
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metHods
Population
Rotterdam Study
The Rotterdam Study is a large prospective population-based cohort study to which all in-
habitants aged 55 years and over of Ommoord, a district of Rotterdam, The Netherlands were 
invited.14 The medical ethics committee of the Erasmus University of Rotterdam approved the 
study and informed consent was obtained from all participants. A total of 7983 individuals 
(response rate 78%) participated in the baseline examinations between 1990-1993 (mean 
age 71±25 years, range 55-106). All individuals were interviewed at home, and invited to visit 
the research centre for further examinations. In the 3rd (1997-1999) and 4th survey (2002-2004) 
cognitive function was assessed at the research centre by use of a dedicated neuropsycho-
logical test battery.
Source Population
The current analyses on inflammation and cognition concern participants who underwent 
the neuropsychological test battery and had blood drawn at the 3rd survey. In the 3rd survey 
4797 individuals participated, of whom 4206 underwent neuropsychological testing. Blood 
samples were obtained in 3993 of these individuals. Individuals with dementia at the 3rd 
survey (n=119) were excluded, resulting in 3874 individuals available for analyses.
Of these 3874 individuals, 2433 individuals completed the neuropsychological test battery 
at the 4th survey, and thus were available for longitudinal analyses. Of the 1441 individuals 
who did not participate, 444 had died, 297 refused to participate, 193 were too ill to visit 
the research centre, 111 could not be contacted and 396 had incomplete data on cognitive 
function tests.
Additional Measurements
Education was measured at the baseline examination (1990-1993), and dichotomised more 
or less than 6 years of schooling. The following measures were all assessed at the 3rd survey 
(1997-1999). Depressive symptoms were assessed during the home interview, by use of a 
depression questionnaire (the 20-item version of the Center for Epidemiological Studies 
Depression Scale (CES-D)). The use of cardiovascular drugs or anti-inflammatory drugs was 
assessed by questionnaire during the home-interview. The presence of cardiovascular dis-
ease was defined as a positive history of myocardial infarction, percutaneous transluminal 
coronary angioplasty (PTCA), coronary artery bypass graft (CABG), stroke, and/or the pres-
ence of angina pectoris or intermittent claudication as assessed by the Rose questionnaire. 
Furthermore, carotid intima medial thickness above 1.0 mm and the presence of plaques in 
the carotid arteries as assessed by ultrasonography15 were used as measures of atherosclero-
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sis. APOE genotypes were assessed as previously described,16 and were available in 3664 of 
the 3874 individuals.
The diagnosis of dementia was made following a three-step protocol.17 In short, two brief 
cognition tests (Mini-Mental State Examination (MMSE)18 and Geriatric Mental State schedule 
(GMS))19 were used to screen all subjects. If persons screened positive (MMSE score<26 or 
GMS organic level>0) they were additionally examined with the Cambridge examination 
for mental disorders of the elderly (Camdex) by a physician who also obtained an interview 
with an informant.20 Subjects who were suspected of having dementia were examined by a 
neuropsychologist if additional neuropsychological testing was required for diagnosis. Final 
diagnosis was made by an adjudication panel.
Leiden 85-plus Study
The Leiden 85-plus Study is a prospective population-based cohort study of inhabitants 
of Leiden, The Netherlands. The Medical Ethical Committee of the Leiden University Medi-
cal Centre approved the study, and informed consent was obtained from all participants. 
Between September 1997 and September 1999, all inhabitants of Leiden born between 
1912 and 1914 (n=705) were contacted within a month after their 85th birthday. A total of 
599 individuals (response rate 87%) agreed to participate. From age 85 till 90 years, annual 
neuropsychological tests were performed during home visits.
Source Population
The current analyses on inflammation and cognition concern participants that underwent 
the neuropsychological test battery and had blood samples drawn at age 85. Five hundred 
ninety nine individuals underwent neuropsychological testing of whom 563 had blood 
samples taken, 29 refused and 7 died before blood samples could be taken. Individuals with 
dementia at age 85, as defined by a clinical diagnosis of the treating physician (n=72), were 
excluded, resulting in 491 individuals available for analyses.
Data on cognitive function with at least one follow-up collection were available in 440 
individuals. At age 86 cognitive function was assessed in 437 individuals, at age 87 in 392 
individuals, at age 88 in 374 individuals, at age 89 in 299 individuals, and at age 90 in 255 
individuals. Of the remaining 51 individuals without follow-up, 35 died before the age of 86 
years, 13 refused to participate, and 3 had no data on cognitive function tests at follow-up 
visits.
Additional Measurements
The following measures were assessed at age 85 years. Education was dichotomised into 
more or less than 6 years of schooling. Depressive symptoms were assessed by use of the 15-
item Geriatric Depression Scale (GDS-15)21 during the home interview. The use of cardiovas-
cular drugs or anti-inflammatory drugs was determined by pharmacy records. The presence 
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of cardiovascular disease was defined as a positive medical history of myocardial infarction, 
arterial surgery, stroke, angina pectoris, and/or intermittent claudication. APOE genotypes 
were assessed as previously described,22 and were available in 479 of the 491 individuals.
Cognitive Function
Global cognitive function was measured by use of the Mini-Mental State Examination (MMSE) 
in both cohorts. In addition, a neuropsychological test battery was used to assess global 
cognitive function, executive function, and memory function. The test battery included the 
abbreviated Stroop test part 3 and the Letter Digit Substitution Task in both cohorts.23
In the Rotterdam Study, word fluency24 was additionally assessed. Since at the third survey 
no separate test was administered to measure memory function, we used the items from the 
MMSE and Geriatric Mental State examination, (GMS-A organic level test)25 that aim to assess 
memory. The thus constructed memory score had a range of 0 (worst score) to 4 points (best 
score).
In the Leiden 85-plus Study memory function (immediate and delayed recall) was assessed 
by use of the 12-Picture Learning Test.26
Compound cognitive test scores were constructed by transforming individual test scores 
into standardised Z-scores (Z-score = (individuals score – mean population score) / SD popu-
lation score). Compound scores were estimated for global cognitive function and executive 
function. Global cognitive function was calculated by averaging the Z-scores of the Stroop 
test, the Letter Digit Substitution Task, the Word Fluency Test and the memory score (in the 
Rotterdam Study), or the Stroop test, the Letter Digit Substitution Task, and the 12-Picture 
Learning Test immediate and delayed recall (in the Leiden 85-plus Study). Executive func-
tion included the Z-scores of the Stroop test and the Letter Digit Substitution Task in both 
cohorts.27
Inflammatory Markers
High sensitivity CRP (hsCRP) was measured by use of a Rate Near Infrared Particle Immunoas-
say (IMMAGE®, Immunochemistry System, Beckman Coulter, USA, detection limit 0.2 mg/l, 
coefficient of variation (CV) 3.2%) in the Rotterdam Study. CRP was measured by use of a fully 
automated Hitachi 747 system (Hitachi, Tokyo, Japan, detection limit 1 mg/l, CV <5%) in the 
Leiden 85-plus Study.
IL-6 plasma levels were determined by a quantitative ELISA technique (Quantikine HS IL-6 
kit, R&D Systems, Oxon, UK, detection limit 0.094 pg/ml, CV 8.7% ) and ACT plasma levels 
by kinetic nephelometry (Behring Nephelometer BN200®, Marburg, Germany, detection limit 
1.5 mg/dl, CV 2.8%) in a random sample of the Rotterdam Study (n=491). IL-6 levels in the 
Leiden 85-plus study were obtained from an ex vivo whole blood stimulation assay at age 
85 years.28 In short, after incubation of venous blood samples at 37°C and 5% CO2 for 24 
hours, supernatants were collected and stored at -80°C until measurement of IL-6 by use of 
Chapter 4.2
76
a standard ELISA (Sanquin, Amsterdam, the Netherlands, detection limit 4 pg/ml, CV 5-10%). 
We used the unstimulated IL-6 levels as an estimate of circulating IL-6 levels. In addition, we 
measured circulating IL-6 levels at age 86 years using the same ELISA.
Statistical Analyses
First, we investigated the cross-sectional association of systemic markers of inflammation with 
cognitive function, with linear regression analyses and with markers of inflammation both in 
categories and as continuous variables in the models. CRP and IL-6 were log-transformed 
because of their skewed distribution.
Second, we used linear regression to investigate the longitudinal association of systemic 
markers of inflammation with cognitive decline, with the annual change of cognitive function 
as dependent and inflammatory markers as independent variables. In the Rotterdam Study, 
annual cognitive decline was calculated as the difference between the test scores at the 4th 
and the 3rd survey divided by follow-up time (mean follow-up 4.6 ± 0.5 years). In the Leiden 
85-plus Study annual cognitive decline was calculated by subtracting test scores at the latest 
follow-up examination from the test scores at age 85 and dividing them by the follow-up 
time (mean follow-up 3.4 ± 1.8 years).
All analyses were adjusted for age (Rotterdam Study only), sex, and education level, because 
these factors strongly relate to cognitive function. On further analysis, we adjusted for body 
mass index, diabetes and prevalent cardiovascular disease. Finally, we tested for interactions 
of inflammatory markers with APOE-ε4, cardiovascular disease and atherosclerosis in the 
association with cognitive function.
resUlts
Table 1 gives principal features of both study populations. Table 2 shows the clinical char-
acteristics of both study samples used for cross-sectional and longitudinal analyses. In the 
sample from the Rotterdam Study mean age was 72.1 years, 58% were women and 29% 
had primary education only. In the Leiden 85-plus Study mean age was 85 years, 65% were 
women and 62% had primary education only. Cognitive function in the Rotterdam Study was 
better than in the participants of the Leiden 85-plus Study, reflecting the younger age range 
and higher education level in the Rotterdam Study.
As expected, participants who were included in the follow-up examinations of the Rot-
terdam Study were younger and had a better cognitive function than the participants of the 
complete sample. Median follow-up was 4.5 years (range 1.5 to 7.1). In the Leiden 85-plus 
Study, individuals with at least 1 year of follow-up had only slightly better cognitive function 
than the participants of the complete sample. Median follow-up was 5.0 years (range 1.0 to 
5.0).
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Inflammatory Markers and Cognitive Function
In the Rotterdam Study, higher CRP and IL-6 levels were associated with worse cognitive 
function (Table 3). Estimates were similar in the Leiden 85-plus Study for CRP, though not 
statistically significant (Table 3). ACT was not related to cognitive function (all p>0.37).
Additionally, we stratified the study populations for the presence or absence of an APOE-ε4 
allele, and according to the presence or absence of cardiovascular disease or atherosclerosis 
at baseline. The association between inflammatory markers and cognitive function did not 
differ between those with or without an APOE-ε4 allele, neither between those with or 
without cardiovascular disease or atherosclerosis. This held true for both cohorts (data not 
shown).
Inflammatory Makers and Cognitive Decline
Table 4 shows the association of CRP and IL-6 with cognitive decline, as measured during 
follow-up. In both cohorts, nearly all point estimates of cognitive function were negative, 
indicating worse outcome, when levels of inflammatory markers at baseline were higher. 
However, there may be an association of IL-6 with memory decline in the Leiden 85-plus Study. 
Higher levels of ACT were not related to a steeper annual cognitive decline (all p>0.19).
Table 5 shows the associations of inflammatory markers with cognitive decline stratified for 
carriers and non-carriers of the APOE-ε4 allele. In the Rotterdam Study, IL-6 was associated 
table 1. Overview of both study populations
rotterdam study leiden 85-plus study
Baseline investigations 1990-1993 1997-1999
inclusion All individuals aged 55 years and 
over, living in Ommoord, a district of 
Rotterdam
All individuals born between 
1912-1914, living in Leiden
Age at baseline 55 years and over (range 55-99) 85 years
cognitive function
Measurements Mini-Mental State Examination Mini-Mental State Examination
Stroop test Stroop test
Letter Digit Substitution Task Letter Digit Substitution Task
Memory score
Word Fluency Test
Immediate and delayed recall of 
the 12-Picture Learning Test
Number of measurements two annual (max. 5)
Measurements used 3rd survey (1997-1999) baseline (1997-1999)
4th survey (2002-2004) latest follow-up examination
Follow-up 4.6 years max. 5 years
markers of inflammation
Measurements High sensitivity CRP CRP
IL-6 unstimulated IL-6
 ACT  
Measured at 3rd survey (1997-1999) baseline
Number 3874 for hsCRP
491 for IL-6 / ACT
491 for CRP
491 for unstimulated IL-6
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table 2. Characteristics at the 3rd survey of the Rotterdam Study and at age 85 of the Leiden 85-plus Study
  rotterdam study leiden 85-plus study
  Study sample at 
3rd survey
(n = 3874)
Study sample at 
3rd survey with 4.6 
year follow-up
(n = 2433)
Study sample 
at baseline
(n = 491)
Study sample 
at baseline with 
at least 1 year 
follow-up
(n = 440)
clinical characteristics  
Age (yrs) 72.1 ± 6.9 70.2 ± 5.7 85 85
Women (%) 58 58 65 67
Low level of education (%) 29 26 62 60
Cardiovascular disease (%) 37 31 62 61
Stroke (%) 5 3 9 8
Present smoking (%) 18 17 15 14
Diabetes (%) 12 10 16 16
medication use
Use of cardiovascular drugs (%) 48 45 53 52
Use of NSAIDs (%) 8 8 28 27
cognitive function
MMSE (points) 27.7 ± 2.0 28.1 ± 1.6 25.4 ± 4.6 25.5 ± 4.4
CES-D (points) 1 (0 - 6) 1 (0 - 5) - -
GDS (points) - - 2 (1 - 3) 2 (1 - 3)
Stroop test part 3 (seconds) 57.5 ± 21.6 53.6 ± 17.6 81.5 ± 32.9 81.1 ± 33.3
Letter Digit Substitution Task 
(correct answers)
26.6 ± 7.1 28.1 ± 6.5 17.3 ± 7.0 17.6 ± 7.0
Word Fluency Test (words) 20.9 ± 5.5 21.8 ± 5.3 - -
Memory Score delayed recall 
(words)
3.2 ± 0.9 3.3 ± 0.8 - -
12-Picture Learning Test 
immediate recall (total pictures 
of 3 trials)
- - 24.4 ± 5.4 24.4 ± 5.5
12-Picture Learning Test delayed 
recall (pictures)
- - 8.9 ± 2.5 8.9 ± 2.5
inflammatory markers
hsCRP (mg/l) 2.42 (1.21 - 4.59) 2.18 (1.14 - 4.23) - -
CRP (mg/l) - - 4 (1-8) 3 (1 - 7)
IL-6 (pg/ml) 2.11 (1.44 - 3.32) a 1.96 (1.37 - 2.88) b - -
Unstimulated IL-6 (pg/ml) - - 11 (0 - 53) 10 (0 - 57)
 ACT (mg/dl) 39.8 ± 11.3 a 38.9 ± 10.8 b - -
Results are presented as percentage, mean ± sd or median (interquartile range). a) In a random sample of 
491 only. b) In a sample of 300. Results in the Rotterdam Study for neuropsychological tests and CRP were 
available in 3874 individuals for MMSE, 3720 for the Stroop test, 3766 for the Letter Digit Substitution Task, 
3802 for Word Fluency, and, 3871 for the Memory Score delayed recall. Results for neuropsychological 
tests, IL-6 and ACT were available in 491 individuals for MMSE, 487 for the Stroop, 489 for the Letter 
Digit Substitution Task, 487 for Word Fluency and 491 for the Memory Score delayed recall. Results in 
the Leiden 85-plus Study for neuropsychological tests and inflammatory markers were available in 491 
individuals for MMSE, 413 for the Stroop test, 408 for the Letter Digit Substitution Task, and, 426 and 425 
for immediate and delayed recall of the 12-Picture Learning Test.
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with a decline in global cognitive function in APOE- ε4 carriers, but not in APOE- ε4 non-
carriers. In the Leiden 85-plus Study, the associations of CRP and IL-6 with global cognitive 
decline and memory decline were stronger in carriers of the APOE- ε4 allele compared to 
non-carriers (p-interaction<0.05). ACT was associated with a decline in executive function 
in APOE- ε4 carriers (annual decline -0.020 [95%CI, -0.039;-0.002]), but not in non-carriers 
(annual decline -0.001 [-0.017; 0.019], p-interaction 0.146).
The presence of cardiovascular disease or atherosclerosis at baseline did not consistently 
influence the relation between inflammatory markers and cognitive decline, in either of the 
two cohorts (data not shown).
Additional analyses
Additional adjustment for symptoms of depression, use of anti-inflammatory drugs, body 
mass index, cardiovascular disease or diabetes did not materially change our results (data not 
shown). Furthermore, in the Rotterdam sample we investigated whether the association of 
inflammatory markers with cognitive function and decline was stronger at old age. We could 
not demonstrate any consistent influence of age on this association.
In this follow-up study on inflammation contributing to cognitive decline, we have 
excluded those who suffered from dementia at baseline (Rotterdam Study: n=119, Leiden 
85-plus Study: n=72). However, when we re-introduced these individuals with dementia at 
baseline into the analyses, the results did not materially change (data not shown).
Next to unstimulated production levels of IL-6 we also measured circulating IL-6 at age 
86 in the Leiden 85-plus Study (n=427). In this sample we repeated all analyses on cognitive 
function and decline with circulating IL-6. The key question was whether we could replicate 
the association between higher unstimulated IL-6 production levels and an increased annual 
cognitive decline, especially in the memory domain. High compared to low circulating IL-6 
levels were associated with an annual decline in MMSE of -0.418 points (-0.829;-0.133) and 
with an annual decline in memory function of -0.254 words (-0.488; -0.019). Corresponding 
estimates for unstimulated IL-6 levels were -0.352 points (95%CI, -0.756;0.061) for the MMSE 
and -0.334 words (-0.588;-0.080) for memory decline. The similar effect sizes suggest that the 
unstimulated production level of IL-6 in whole blood samples is a valid estimate of circulating 
IL-6.
discUssion
We found that systemic levels of CRP and IL-6 were only moderately associated with esti-
mates of global cognition and executive function in cross-sectional analyses. Systemic levels 
of IL-6 were related to a longitudinal decline in memory function in the Leiden 85-plus study 
only. When compared to non-carriers, in APOE- ε4 carriers increasing IL-6 levels tended to be 
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more strongly associated with the annual decline in global cognition and memory function. 
However, due to the large number of comparisons made and the large sample size, these 
results may be due to chance.
Previous studies also demonstrated minor associations between inflammatory markers 
and cognitive decline.6-9,29 However, the effect size being modest does not imply that the 
involvement of systemic inflammation in the pathophysiology of cognitive decline is mod-
est as well.30 In fact, the consistent finding of this association in different populations may 
suggest that inflammation is involved in the pathophysiology of cognitive decline. However, 
we cannot rule out the possibility that both inflammatory activation and cognitive decline 
reflect the consequence of an underlying common disease process. In contrast, these find-
ings do imply that measurement of inflammatory markers is not suitable for risk prediction of 
cognitive decline in clinical practice.
Dementia, the end stage of severe cognitive decline, develops over a long pre-clinical 
period. Therefore its association with inflammatory markers may reflect a consequence of the 
disease process, rather than a causal path. This may play a role both in cross-sectional studies 
and studies with a relatively short follow-up. In order to limit the possibility that individuals 
with dementia would drive the association between inflammatory markers and cognition, 
we vigorously excluded subjects with dementia from the analyses. It cannot be excluded 
that subjects who are early in the dementia process and do not fulfil the criteria for dementia 
yet, drive the associations as described here. However, when we repeated the analyses and 
included those with dementia at baseline, the observed associations did not change. We 
previously demonstrated in the Rotterdam Study that ACT was strongly related to incident 
dementia, while CRP and IL-6 were only moderately associated to dementia.5 The discrepancy 
with our current finding suggest that timing is important in the association of inflammatory 
markers with cognitive decline and dementia. Possibly, inflammation can only predict the 
late stages of cognitive decline, that of dementia, while it is not suitable for risk stratification 
of early cognitive decline.
We found a trend towards a stronger association of inflammatory markers with cognitive 
decline in carriers of the APOE-ε4 allele. This is in agreement with a previous finding that the 
APOE- ε4 allele is associated with an impaired response to cerebral damage,31 which may lead 
to a steeper decline of cognitive function. However, we only observed significant interactions 
in the Leiden 85-plus sample, which may imply an important influence of age on the relation 
between inflammatory markers and cognitive decline. However, formal testing of this sug-
gestion did not demonstrate a stronger association of inflammatory markers with cognitive 
decline at old age. Previously, the LASA study investigated whether APOE- ε4 modulates 
the association between inflammatory markers and cognitive decline,6 and did not find an 
interaction between APOE- ε4, inflammatory markers and cognitive decline. Taken together, 
the effect of the APOE- ε4 allele on the relation between inflammation and cognition needs 
further investigation.
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We did not observe an interaction of atherosclerosis or cardiovascular disease in the as-
sociation of inflammatory markers with cognitive function and decline. This is in contrast to 
previous results from the Leiden 85-plus Study, which showed that inflammatory markers 
interact with atherosclerosis in their association with cognitive decline.32 However, these 
results were derived from cross-sectional data, and are therefore more difficult to interpret 
with respect to causality.
Our study had several strengths. First, we had data on inflammation and cognitive function 
in a large population-based sample of 3874 individuals from the Rotterdam Study over 4.6 
years of follow-up, and of 491 individuals of the Leiden 85-plus Study, with annual follow-
up measures over a period of 5 years. Second, we measured cognitive function by use of 
a neuropsychological test battery which measures separate cognitive domains -notably 
executive and memory function as well as global function-, and used cognitive decline as an 
early indicator of the dementia process. Third, by combining data from two population-based 
studies with a different age-range, we can conclude that the association of inflammatory 
markers with cognition is present over a large age range.
Our study had also several limitations. First, plasma levels of CRP, IL-6 and ACT were only 
measured once, which may have diluted the associations we found, and may thus have lead 
to an underestimation of the risk estimates. Second, different assays were used to determine 
CRP levels. The discriminative power of the Rotterdam study for the analyses including CRP 
was larger due to both the sample size and the use of a high sensitivity CRP assay. This may 
explain why we could not replicate significant findings in both study samples. Third, in the 
Leiden 85-plus Study we used unstimulated IL-6 production in a whole blood assay as an 
estimate of circulating plasma IL-6 levels. Though these production levels are clearly higher 
when compared to circulating plasma levels, we have demonstrated it to be a good estimate 
of plasma IL-6 levels. Fourth, we have performed a number of statistical analyses, which 
carries the possibility of significant findings by chance, i.e., caused by random type 2 errors 
produced by the large sample size and number of statistical test performed. Although, our 
main interest was to replicate our findings in two independent populations, which automati-
cally doubled the number of analyses performed, and the analyses were based on an a priori 
hypotheses, a stricter p-value, for instance of <0.01, may be more appropriate to use for these 
analyses. With this stricter interpretation statistical significance in the prospective analyses 
would have been lost.
Although our cohorts were population-based and prospectively followed, selection bias 
may have occurred by selective non-response. Probably the participation rate was lowest 
among subjects with cognitive impairment. Individuals with follow-up data had a better 
cognitive performance than those who did not return for follow-up examinations, especially 
in the Rotterdam Study. This suggests that the observed cognitive decline is probably lower 
than the actual decline, and therefore, that we may have underestimated the associations 
with the inflammatory markers.
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In conclusion, systemic markers of inflammation are only moderately associated with cog-
nitive function and decline. Our data show some suggestion that these associations may be 
stronger in the presence of the APOE- ε4 allele. However, these results should be interpreted 
with care, and may be due to chance. Systemic markers of inflammation are not suitable to 
predict individual risk of cognitive decline.
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4.3
Serum Uric Acid and Cognitive Function and Dementia
ABstrAct
Background: Uric acid is a risk factor of cardiovascular disease, as well as a major natural 
antioxidant, prohibiting the occurrence of cellular damage. The relation between uric acid 
and cognitive decline, in which both vascular mechanisms and oxidative stress are thought 
to play a role, is unknown.
methods: We assessed the relation between serum uric acid levels and the risk of subsequent 
dementia in a prospective population-based cohort study among 4618 participants aged 55 
years and over. Additionally, we investigated the relation between serum uric acid and cogni-
tive function later in life (on average 11.1 years later) in a subsample of 1724 participants 
who remained free of dementia during follow-up. All analyses were adjusted for age, sex, and 
cardiovascular risk factors.
results: Our data showed that only after correcting for several cardiovascular risk factors, 
higher serum uric acid levels were associated with a decreased risk of dementia (HR, adjusted 
for age, sex and cardiovascular risk factors, 0.89 (95% confidence interval (CI) 0.80-0.99) per 
standard deviation (SD) increase in uric acid). In participants who remained free of dementia, 
higher serum uric acid levels at baseline were associated with better cognitive function later 
in life, for all cognitive domains that were assessed (adjusted difference in z-score (95%CI) 
per SD increase in uric acid 0.04 (0.01;0.08) for global cognitive function; 0.03 (-0.01;0.07) for 
executive function; and 0.07 (0.02;0.12) for memory function), but again only after correcting 
for cardiovascular risk factors.
conclusion: Notwithstanding the associated increased risk of cardiovascular disease, higher 
levels of uric acid are associated with a decreased risk of dementia and better cognitive func-
tion later in life.
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introdUction
Uric acid is associated with an increased risk for myocardial infarction, stroke, and cardio-
vascular mortality.1-3 Suggested mechanisms for this are a uric-acid-induced stimulation of 
vascular smooth muscle cell proliferation; the inflammatory properties of soluble uric acid; 
and the direct effect of uric acid on endothelial function by impairing nitric oxide produc-
tion.1,2,4 However, as a major natural antioxidant, uric acid also accounts for a substantial part 
of the antioxidative capacity of the plasma.5 This beneficial property might reduce oxidative 
stress and protect against the detrimental effect of free radicals.
Both vascular pathology and oxidative stress have been associated with an increased risk 
of dementia and cognitive impairment.6-8 Therefore, the different properties of uric acid 
might have contradictory effects on the risk of dementia and on cognitive function. Previous 
studies have shown that levels of serum uric acid in subjects with mild cognitive impairment 
(MCI) and in patients with Alzheimer’s disease (AD) are lower than those in healthy controls, 
suggesting that uric acid may have a protective effect.9,10 To our knowledge, no prospective, 
population-based studies have investigated the relation between serum uric acid and the 
risk of dementia or cognitive function later in life.
We hypothesized an association between serum uric acid and a decreased risk for demen-
tia, and better cognitive function later in life based on the antioxidative properties of uric 
acid, possibly masked by the uric acid-related vascular pathology that is associated with 
worse cognitive function. Therefore, we investigated the association between serum uric 
acid levels and the risk of dementia as well as the relation between serum uric acid levels and 
several domains of cognitive function later in life, in the Rotterdam Study, a large prospective 
population-based cohort study in subjects aged 55 years and over, for whom several known 
cardiovascular risk factors were available.
metHods
Population
The Rotterdam Study is a large ongoing prospective population-based cohort study that 
is being conducted among all inhabitants aged 55 years and over of Ommoord, a district 
of Rotterdam, the Netherlands.11 The study was conducted according to the Declaration of 
Helsinki, and the appropriate Medical Ethics Committees approved the study protocols. A 
written informed consent was obtained from all participants. Of 10,275 eligible subjects, 
7983 individuals (78%) participated in the baseline examinations between 1990-1993 (mean 
age (SD) 71 (25) years, range 55-106 years). All participants were interviewed at home, and 
visited the research centre for further examinations. At the 4th survey (2002-2004) cognitive 
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function was more extensively assessed with a dedicated neuropsychological test battery. 
The entire cohort was continuously monitored for incident dementia.
Study population
Uric acid assessments were performed only until December 31, 1992, when they were stopped 
because of financial constraints, leaving 5150 participants for whom baseline uric acid levels 
were available.3 Participants with dementia (n=278), stroke (n=126) or missing cognitive test 
data (n=128) at baseline were excluded. This resulted in a sample of 4618 participants avail-
able for the analyses on the relation between uric acid and the risk of dementia (Figure 1).
More than 10 years later, at the 4th survey in 2002-2004, we assessed cognitive function 
with a neuropsychological test battery in all surviving, non-demented, consenting partici-
pants. Of these 4618 participants with uric acid assessments at baseline, 457 had developed 
dementia during follow-up; 1315 had died; 846 refused the in person examination; 186 had Pagina 91:  
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Figure 1. Description of the study population.
Of the 5150 participants whose serum uric acid measurements were available, 532 were excluded at 
baseline (1990-1993): 278 were diagnosed with dementia, and 126 with a stroke; 128 did not have 
baseline cognitive measurements available. This resulted in 4618 participants in the total sample who 
were at risk for dementia at baseline. Of these 4618 participants, 2894 did not participate in the 4th survey: 
457 had developed dementia during follow-up, 1315 had died, 846 refused the in person examination, 
186 did not have a complete cognitive test assessment, and 90 participants could not be contacted. This 
resulted in a subsample of 1724 participants who had complete data on the neuropsychological test 
battery available at the 4th survey.
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an incomplete cognitive test assessment; and 90 participants could not be contacted. The 
subsample available for the analyses on the relation between uric acid levels and cognitive 
function later in life therefore consisted of 1724 participants who remained free of dementia 
during follow-up and had both baseline uric acid levels and cognitive test data available 11 
years later (Figure 1).
Uric acid
Nonfasting blood was collected and centrifuged. Within 30 minutes, the blood was centri-
fuged for 10 minutes at 3000 rotations per minute. Subsequently, the serum was stored at 
-20ºC for one week until uric acid activity was determined with a Kone Diagnostica reagent 
kit and a Kone autoanalyzer.12 To check calibration, after every 10 samples, three control 
samples were included; if the average values of the control samples of each run (100 samples) 
were not within 2.5% of the true value, the run was repeated. Day-by-day variation had to be 
within 5%. Finally, we compared the serum uric acid levels in our population with those in 
two other large population-based studies.1,13
Diagnosis of dementia
At baseline and during follow-up examinations, dementia was diagnosed similarly accord-
ing to a three-step protocol.14 The total cohort was continuously monitored for incident 
dementia through linkage between the study database and the digitalized medical records 
from general practitioners and the Regional Institute for Outpatient Mental Health Care. The 
diagnosis of dementia was made in accordance with internationally accepted criteria for de-
mentia (DSM-III) by a panel consisting of a neurologist, a neuropsychologist, and a research 
physician.
Cognitive function
Global cognitive function was measured with the Mini-Mental State Examination (MMSE) 
at baseline.15 In addition, a dedicated neuropsychological test battery was used to assess 
global cognitive function, executive function, and memory function at the 4th survey (2002-
2004). Compound cognitive test scores were constructed by transforming individual test 
scores into standardized Z-scores (Z-score = (individuals score – mean population score) / 
SD population score).16 Global cognitive function was calculated by averaging the Z-scores 
of the Letter Digit Substitution Task (LDST),17 the Word Fluency Test (WFT),18 the Stroop test 
(sum of the reading, colour naming and interference subtask),19 and the 15-Word Learning 
Test immediate and delayed recall.20 Executive function included the Z-scores of the Stroop 
test (interference subtask), the LDST, and the WFT. Memory function included the Z-score of 
the 15-WLT immediate and delayed recall.16
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Additional measurements
Blood pressure was measured twice at baseline with a sphygmomanometer after 5 min-
utes of seated rest. The average of these two measurements, separated by a count of the 
pulse rate, was used in the analyses. Total and high-density lipoprotein cholesterol levels 
were measured at baseline in nonfasting blood with an automated enzymatic procedure. 
During the home interview, smoking status (classified as current, former or never), history 
of diabetes mellitus and history of cardiovascular disease (defined as history of myocardial 
infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, 
peripheral artery disease, cerebrovascular accident or atrial fibrillation) were assessed. Level 
of education was measured at baseline and dichotomized into primary education or less, 
and more than primary education The waist/hip-ratio was calculated by dividing the waist 
circumference by the hip circumference.
Statistical analyses
We used Cox proportional hazard models to calculate hazard ratios with 95% confidence 
intervals (95%CI) for the association between uric acid and risk of dementia. Hazard ratios 
were calculated for quartiles of uric acid (with the lowest quartile as the reference) as well 
as continuously, per SD increase in uric acid level. Participants were followed from date of 
study entry until age of diagnosis of dementia, age at death or age at end of study, whichever 
came first. Because serum uric acid is associated with stroke,3 and stroke is associated with 
risk of dementia,21 we censored incident stroke cases. The relation between baseline uric acid 
levels and cognitive function later in life was assessed with linear regression models, with uric 
acid as an independent, and cognitive function as the dependent variable, and with analyses 
of covariance (ANCOVA). All analyses were adjusted for age, sex, level of education and ad-
ditionally for several known cardiovascular risk factors. Analyses were carried out using the 
SPSS statistical package (release 11.1; SPSS inc., Chicago, Illinois).
resUlts
The baseline characteristics of the total sample of 4618 participants and the subsample of 
1724 participants for whom complete data on the neuropsychological test battery were 
available at the 4th survey, are shown in Table 1. The mean age of the total sample of 4618 
participants was 69.4 years, 61 percent were female and the mean serum level of uric acid 
was 322.3 μmol/L. Thirty-two percent of these participants had a history of cardiovascular 
disease. During a total of 41,651 person-years of follow-up (mean (SD) 9.0 (3.5)), 457 new 
cases of dementia were detected. Not surprisingly, the 1724 non-demented participants with 
complete cognitive test data at the 4th survey were at baseline younger, had lower levels 
of uric acid, less often a history of cardiovascular disease and a better cognitive function 
Chapter 4.3
94
compared to the remainder of the cohort (Table 1). However, after adjustment for several 
vascular risk factors and markers of vascular disease (serum creatinine levels, systolic blood 
pressure, ever smoking, total cholesterol and HDL-cholesterol levels, diabetes mellitus, waist/
hip ratio and prevalent cardiovascular disease), there was no significant difference in baseline 
uric acid levels anymore between the 1724 participants with complete cognitive test data at 
the 4th survey and the rest of the cohort.
In the total sample of 4618 participants, higher baseline levels of uric acid were not as-
sociated with the risk of dementia in the analyses that were adjusted for age and sex only. 
However, when we accounted for vascular risk factors and markers of vascular disease (serum 
creatinine levels, systolic blood pressure, ever smoking, total cholesterol and HDL-cholesterol 
levels, diabetes mellitus, waist/hip ratio and prevalent cardiovascular disease) higher uric 
table 1. Baseline characteristics (1990-1993)
Total 
sample
Complete data of cognitive function available at 4th survey(2002-2004)
(n = 4618)
Yes
(n = 1724)
No
(n = 2894)
Incident 
dementia
(n = 457)
Died
(n = 1315)
Refused
(n = 846)
Incomplete 
cognitive 
data
(n = 186)
Could 
not be 
contacted
(n = 90)
Age (years) 69.4 (8.6) 64.1 (5.7) 76.2 (7.3) 74.5 (8.7) 68.5 (7.0) 67.6 (7.0) 73.5 (8.8)
Gender (% female) 61 61 70 51 69 61 80
Serum uric acid level 
(μmol/L)
322.3
(80.5)
312.4
(73.4)
317.4
(78.9)
342.1
(87.8)
316.2
(77.6)
315.9
(78.3)
315.7
(86.6)
MMSE-score (points) 27.7 (1.9) 28.2 (1.4) 26.7 (2.2) 27.3 (2.1) 27.7 (1.8) 28.0 (1.7) 27.5 (2.1)
Low level of education 
(%)
40 29 55 47 44 37 51
Creatinine plasma 
level (μmol/L)
82.8
(21.9)
80.6
(14.0)
83.7
(25.5)
88.0
(31.3)
79.6
(14.0)
79.6
(12.7)
81.4
(18.1)
Systolic blood 
pressure (mm Hg)
138.9
(21.8)
133.5
(19.8)
141.9
(21.7)
144.2
(23.8)
141.0
(20.5)
133.5
(19.4)
142.8
(21.2)
Total cholesterol 
(mmol/L)
6.6
(1.2)
6.7
(1.2)
6.5
(1.2)
6.4
(1.3)
6.9
(1.2)
6.7
(1.2)
6.6
(1.1)
High-density 
cholesterol (mmol/L)
1.3
(0.4)
1.4
(0.4)
1.3
(0.3)
1.3
(0.4)
1.4
(0.4)
1.4
(0.4)
1.3
(0.4)
Diabetes mellitus (%) 11 6 15 18 9 10 12
Smoking (% ever) 65 67 56 68 63 63 39
Waist/hip ratio 0.91
(0.09)
0.89
(0.09)
0.91
(0.09)
0.93
(0.09)
0.90
(0.09)
0.91
(0.09)
0.90
(0.09)
Cardiovascular 
disease (%)
32 19 42 48 29 27 39
Data are presented as means (SD) or percentages. The total sample represents the 4618 participants who 
were at risk of developing dementia. Of these 4618 participants, 1724 participated at the 4th survey (2002-
2004) and underwent cognitive assessments during this follow-up examination. Of the 2894 participants 
who did not have cognitive data available at the 4th survey, 457 had developed dementia, 1315 had died, 
846 refused the in person examination, 186 did not have a complete cognitive test assessment, and 90 
participants could not be contacted. (MMSE = Mini-Mental State Examination).
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acid levels were associated with a lower risk of dementia (hazard ratio (95%CI) for the highest 
versus the lowest quartile of uric acid 0.74 (0.56-0.99), Table 2).
In the subsample of 1724 participants, higher baseline levels of uric acid were associated 
with better cognitive function later in life (on average 11.1 years later), but only after ad-
justment for cardiovascular risk factors (Figure 2). The difference in z-score (95%CI) per SD 
increase in uric acid was 0.04 (0.00-0.07) for global cognition; 0.02 (-0.02-0.06) for executive 
function; and 0.06 (0.02-0.11) for memory function. There was a significant trend (p<0.05) 
over the quartiles of serum uric acid for global cognition and memory function, indicating 
better cognition for participants with higher levels of serum uric acid.
Furthermore, persons with higher levels of serum uric acid at baseline were more likely 
to have cardiovascular disease (age- and sex-adjusted odds ratio (95%CI) for cardiovascular 
disease for the highest versus the lowest quartile of uric acid 2.21 (1.82;2.67)), and had an 
increased risk to die from cardiovascular diseases (age- and sex-adjusted hazard ratio (95%CI) 
for cardiovascular mortality for the highest versus the lowest quartile of uric acid 1.73 
(1.37;2.17)). These associations remained after adjusting for serum creatinine, systolic blood 
pressure, ever smoking, total cholesterol, HDL-cholesterol, diabetes mellitus, waist/hip ratio 
and (for the cardiovascular mortality analysis only) prevalent cardiovascular disease.
discUssion
In this large, population-based cohort study, serum uric acid levels were not associated with 
the risk of dementia or with cognitive function later in life. However, after adjustment for 
several cardiovascular risk factors, higher serum uric acid levels were associated with a de-
creased risk of dementia and better cognitive function later in life. The age- and sex-adjusted 
analyses showed no clear association between serum uric acid levels and the risk of dementia, 
or cognitive function later in life. However, higher levels of uric acid were associated with an 
table 2. Uric acid and the risk of dementia
Uric acid Model 1a
(457 cases)
Model 2b
(457 cases)
Per SD increase uric acid 0.93 (0.84-1.03) 0.89 (0.80-0.99)*
1st Quartile 1 (reference) 1 (reference)
2nd Quartile 0.97 (0.75-1.26) 0.95 (0.73-1.23)
3rd Quartile 0.94 (0.73-1.22) 0.90 (0.69-1.18)
4th Quartile 0.81 (0.62-1.05) 0.73 (0.55-0.97)*
p-trend 0.114 0.030
Estimates indicate hazard ratios with corresponding 95% confidence intervals.
aAdjusted for age, sex and level of education.
bAdjusted for age, sex, level of education serum creatinine levels, systolic blood pressure, ever smoking, 
total cholesterol and HDL-cholesterol levels, diabetes mellitus, waist/hip ratio, cardiovascular disease, all 
at baseline. * p< 0.05
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Figuur 2. 
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Figure 2. Relation between plasma uric acid levels in quartiles and cognitive function later in life (n= 
1724).
Z-scores (standard error of the mean) for the different cognitive domains are plotted for the quartiles 
of plasma uric acid levels. Linear regression models and analyses of covariance (ANCOVA) were used, 
adjusted for age, sex, level of education, serum creatinine, systolic blood pressure, total cholesterol and 
high-density cholesterol levels, diabetes mellitus, ever smoking, waist/hip-ratio, prevalent cardiovascular 
disease.
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increased risk of cardiovascular disease and mortality. After adjustment for several cardiovas-
cular risk factors, the protective effect of uric acid was unmasked: higher levels of uric acid 
were associated with a lower risk of dementia and better cognitive function later in life.
We know of only one other population-based study that has examined the relation between 
serum uric acid and cognitive function. This study reported an association between higher 
levels of uric acid and impaired memory function in a sample of 96 community dwelling 
participants, which is not in line with our results.22 The relatively small sample size and the 
limited number of cardiovascular risk factors for which the analyses were adjusted, may have 
made it hard to separate the contradictory properties of uric acid in relation to cognitive 
function in this study.
The strengths of our study include its prospective, population-based design with a large 
study population, the nearly complete dementia-follow-up, the dedicated neuropsychologi-
cal test battery that was used and the large number of cardiovascular risk factors that were 
assessed.
Our study also had some limitations. First, the assessment of uric acid had been stopped 
before all participants could visit the research centre. However, because all participants were 
invited in random order, this is unlikely to have affected our results. Furthermore, the mean 
levels of serum uric acid measured in our study population were comparable with those in 
two other large population-based studies: NHANES I and the Cardiovascular Study in the 
Elderly.1,13 Second, the association between uric acid and cognitive function later in life was 
based on the assessment of serum uric acid at baseline and the measurement of cognitive 
function more than 10 years later. Participants with relatively low levels of uric acid and good 
cognitive function at baseline were more likely to have complete data on the neuropsycho-
logical test battery at the 4th survey. The selective attrition of participants with relatively high 
levels of uric acid and concurrent worse cognitive function did not surprise us, as uric acid 
is an important risk factor for cardiovascular mortality, myocardial infarction and stroke,1-3 
but could have affected our results. However, after adjustment for several cardiovascular risk 
factors, there was no longer a significant difference in uric acid level between participants in 
the subsample and participants who did not have cognitive tests available at the 4th survey. 
Therefore, selective attrition is unlikely to be the only explanation for our results.
In conclusion, we found in a prospective population-based cohort study that higher serum 
uric acid levels are related to a decreased risk of dementia and better cognitive function later 
in life, but only after adjustment for several cardiovascular risk factors. This corroborates the 
notion that oxidative stress is involved in the pathogenesis of dementia and cognitive impair-
ment and suggests a possible protective role for antioxidants such as uric acid.
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5.1
Plasma Amyloid Beta Peptides 
and the Risk of Cognitive Decline
ABstrAct
Background: The plasma Aβ1-42/Aβ1-40 ratio has been suggested as a premorbid biomarker 
to identify people who are at increased risk of developing dementia. We investigated if the 
plasma Aβ1-42/Aβ1-40 ratio is not only associated with the risk of dementia, but also with cogni-
tive decline at large.
methods: We studied the relation between baseline plasma Aβ1-42 and Aβ1-40 levels and the 
risk of dementia in 1756 participants of a prospective population-based cohort study and 
examined the influence of time-to-event on this association. Furthermore, we studied the 
relation between plasma Aβ1-42 and Aβ1-40 levels at baseline and the decline in cognitive func-
tion in 1452 participants during an average follow-up of 8.0 years.
results: Participants with a lower plasma Aβ1-42/Aβ1-40 ratio were at an increased risk of de-
mentia, but the risk increase diminished with time since blood-draw. There was no association 
between the plasma Aβ1-42/Aβ1-40 ratio level and the risk of cognitive decline in participants 
who did not develop dementia during follow-up.
conclusion: The risk of dementia associated with a lower plasma Aβ1-42/Aβ1-40 ratio is particu-
larly increased within the first years after blood-draw. Assessment of the plasma Aβ1-42/Aβ1-40 
ratio alone is not sensitive enough to identify people at risk for cognitive decline at large.
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introdUction
Peripheral levels of amyloid β peptides have been associated with an increased risk of de-
mentia.1-6 Furthermore, plasma Aβ1-42 levels selectively decline compared to the Aβ1-40 levels 
in the presymptomatic period of the disease, possibly reflecting the deposition of Aβ1-42 in 
the brain.2,3
Graff-Radford et al. suggested that the plasma Aβ1-42/Aβ1-40 ratio might be a useful pre-
morbid biomarker to identify people who are at increased risk of developing dementia and 
cognitive decline.5
We considered that if the plasma Aβ1-42/Aβ1-40 ratio indeed reflects the selective deposition 
of Aβ1-42 in the brain, it might be a relatively late marker in the presymptomatic stages of the 
disease. We hypothesized that although the plasma Aβ1-42/Aβ1-40 ratio can mark an increased 
risk of dementia,4 it may not or less associate with earlier stages of presymptomatic disease.
Therefore, we examined whether the relation between the plasma Aβ1-42/Aβ1-40 ratio and 
the risk of dementia depends on the time between blood draw and onset of dementia. Ad-
ditionally, we assessed whether the plasma Aβ1-42/Aβ1-40 ratio related to the risk of cognitive 
decline beyond the cognitive decline seen in people who develop clinical dementia.
metHods
Population
The Rotterdam Study is a prospective population-based cohort study that was conducted 
among all inhabitants aged 55 years and over of Ommoord, a district of Rotterdam, The 
Netherlands.7 The study was conducted according to the Declaration of Helsinki, and the ap-
propriate Medical Ethics Committees approved the study protocol. Written informed consent 
was obtained from all participants. As described previously, we assessed plasma amyloid β 
levels in a random sample of 1756 participants of the Rotterdam Study who were free of 
dementia and had their blood drawn at baseline (1990-1993).4 They were all followed for 
incident dementia until the end of 2004.
For 34 of the these 1756 people we did not have cognitive test scores at baseline and 270 
persons did not have at least one follow-up assessment of cognitive function, leaving 1452 
people available for the analyses on the risk of cognitive decline.
Plasma amyloid β levels
At baseline, non-fasting blood samples were obtained into vacutainers containing sodium 
citrate. These samples were put on ice immediately and centrifuged within 60 minutes and 
aliquots of plasma were stored at -80˚ C. Plasma levels of Aβ were determined by a double-
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antibody sandwich enzyme-linked immunosorbent assay (ELISA) method (Pfizer, USA).4 The 
detection limits were 5-100 pg/mL for Aβ1-42 and 10-1000 pg/mL for Aβ1-40.
Diagnosis of dementia
At baseline and during follow-up examinations, dementia was diagnosed similarly according 
to a three-step protocol which has been described elsewhere.4 The diagnosis of dementia 
was made in accordance with internationally accepted criteria for dementia (DSM-III) by a 
panel consisting of a neurologist, a neuropsychologist, and a research physician.
Cognitive decline
Cognitive function was assessed at the research center. Global cognitive function was 
measured with the Mini-Mental State Examination (MMSE)8 at baseline (1990-1993) and dur-
ing three follow-up examinations in 1993-1994; 1997-1999; and 2002-2004. We calculated 
individual rates of decline in MMSE-score on basis of a minimum of two and a maximum of 
four MMSE-scores with a random-effects model (SAS 6.12, PROC MIXED; SAS Institute, Cary, 
NC). We used all baseline and follow-up MMSE-measurements as outcome variable, the time 
of measurement as independent variable with time at baseline examination as t = 0, and the 
intercept and time of MMSE measurements as random effects. The estimated fixed effect and 
the individual random effect were added to obtain the estimated slopes and intercepts of the 
individual MMSE scores.9 Participants with the largest decline in cognitive function, defined 
as an individual rate of decline in MMSE-score during follow-up (mean (SD) 8.0 (3.8) years) in 
the top 25% of the distribution, were classified as cognitive decliners.
Additional measurements
Plasma creatinine concentrations were measured with an automated enzymatic procedure 
(Roche, Mannheim, Germany). Genotyping for APOE genotype was done on coded DNA 
specimens.
Statistical analyses
We studied whether the relation between the plasma Aβ1-42/Aβ1-40 ratio and the risk of de-
mentia varied with time-to-event in the sample of 1756 participants, using Cox’ proportional 
hazard models. Especially, we investigated the risk of dementia associated with the plasma 
Aβ1-42/Aβ1-40 ratio within the first 5 years after blood-draw; 5-10 years after blood-draw; and 
more than 10 years after blood-draw.
We investigated the association between plasma Aβ1-42 and the risk of cognitive decline 
across tertiles of plasma Aβ1-40 for the 1452 participants with at least one follow-up assess-
ment of cognitive function with logistic regression. To examine whether associations were 
driven by persons who actually developed dementia, these analyses were repeated after we 
had excluded persons with incident dementia.
Chapter 5.1
106
All analyses were adjusted for age, sex and additionally for plasma creatinine concentration 
and APOE genotype. Analyses were performed using SPSS (release 12.0.1; SPSS inc., Chicago, 
Illinois) and SAS (release 6.12 ; SAS Institute, Cary, NC).
resUlts
Characteristics of the 1756 participants in the cohort at risk for dementia and of the 1452 
participants in whom we could assess cognitive decline are shown in Table 1. Of the 1756 
participants, 166 developed dementia during a mean follow-up of 9.3 years. By definition, of 
table 1. Baseline characteristics
Total cohort at risk for 
dementia
Total cohort at risk for
cognitive decline
No 1756 1452
Age (years) 68.6 ± 8.6 67.4 ± 8.0
Women (%) 61 60
Aβ1-42 (pg/mL) 17.8 (14.7-21.7) 17.5 (14.5-21.2)
Aβ1-40 (pg/mL) 192.0 (163.0-228.0) 189.0 (160.0-222.0)
Aβ1-42/Aβ1-40 ratio 0.09 (0.08-0.11) 0.09 (0.08-0.11)
Creatinine (µmol/L) 82.2 ± 17.2 81.9 ± 16.5
MMSE-score (points) 27.7 ± 1.8 27.9 ± 1.7
Data are presented as mean ± SD, percentage or median (IQR)
Abbreviations: MMSE, Mini-Mental State Examination; SD, standard deviation ; IQR, interquartile range
Hoofdstuk 5.1 
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Figure 1. 
Figure 1. Hazard ratio’s for dementia by levels of Aβ1-42 and Aβ1-40 peptides.
Cox’ proportional hazard models were used, adjusted for age and sex. Tertile combination 1-1 was the 
reference tertile combination. The figure on the left (A) shows the relation between Aβ peptides and 
the risk of dementia in the first 5 years of follow-up for 262 participants. Mean follow-up was 2.6 years 
during which 66 cases of dementia developed. The figure in the middle (B) shows the relation between 
Aβ peptides and the risk of dementia after 5-10 years of follow-up for 296 participants. Mean follow-up 
was 7.7 years during which 64 cases of dementia developed. The figure on the right (C) shows the relation 
between Aβ peptides and the risk of dementia after more than 10 years of follow-up for 1198 participants. 
Mean follow-up was 11.2 years during which 36 cases of dementia developed.
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the 1452 participants with repeated cognitive test data, 363 participants fulfilled the criteria 
for cognitive decline during a mean follow-up of 8.0 years.
Figure 1 shows that the participants who had a plasma Aβ1-42 level in the lowest tertile of 
the distribution in combination with a plasma Aβ1-40 level in the highest tertile of the distribu-
tion were at increased risk of developing dementia but that this increased risk dwindled with 
increasing duration of follow-up (compared to persons with both plasma Aβ1-42 and Aβ1-40 
levels in the lowest tertile of the distribution, age- and sex-adjusted hazard ratio for dementia 
with onset within 5 years after Aβ-measurement 5.97 (95% CI 1.87;19.03); for dementia with 
onset 5-10 years after Aβ-measurement 4.53 (95% CI 1.00;20.59); and for dementia with onset 
more than 10 years after Aβ-measurement 2.27 (95% CI 0.28;18.37).
Figure 2A shows that participants who had a plasma Aβ1-42 level in the lowest tertile of the 
distribution in combination with a plasma Aβ1-40 level in the highest tertile of the distribu-
tion, were more likely to show cognitive decline (age- and sex-adjusted odds ratio compared 
to persons with both plasma Aβ1-42 and Aβ1-40 levels in the lowest tertile of the distribution 
2.58 (95% CI 1.06;6.40). This appeared entirely due to people developing dementia, as after 
exclusion of persons who developed dementia during follow-up, the plasma Aβ1-42/Aβ1-40 
ratio was no longer associated with the risk of cognitive decline (age- and sex-adjusted odds 
ratio for lowest Aβ1-42 and highest Aβ1-40 tertile versus the reference combination 0.67 (95% 
CI 0.14;3.15); figure 2B.
Additional adjustments for plasma creatinine concentrations and APOE genotype did not 
affect any of the estimates.
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Figure 2.
A B 
Figure 2. Risk of cognitive decline according to tertiles of baseline plasma Aβ1-42 and Aβ1-40 levels.
Logistic regression models were used, adjusted for age and sex. Cognitive decline was defined as an 
annual decline in cognitive function in the top 25% of the distribution. Tertile combination 1-1 was 
the reference tertile combination. On the left (A) the relation between tertile combination and risk of 
cognitive decline is shown for the total sample (n = 1452). On the right (B), the relation between tertile 
combination and the risk of cognitive decline is shown for the sample without incident dementia cases (n 
= 133) and therefore includes 1319 participants.
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discUssion
We showed that although a lower plasma Aβ1-42/Aβ1-40 ratio is associated with a higher risk 
of incipient dementia, this risk diminishes with increasing time-to-event. Furthermore, the 
plasma Aβ1-42/Aβ1-40 ratio was not associated with the risk of cognitive decline in persons who 
did not develop dementia during follow-up. These findings suggest that although the plasma 
Aβ1-42/Aβ1-40 ratio may mark a relatively late stage in the preclinical development of dementia, 
it is not an adequate marker of the risk of dementia or cognitive decline in earlier stages of 
the preclinical disease process.
Some studies reported strong associations between the plasma Aβ1-42/Aβ1-40 ratio and the 
risk of dementia,4,5 yet others found a relation between higher plasma Aβ1-42 levels and an in-
creased risk of dementia.1,2 Together with our present findings, these discrepancies challenge 
the usefulness of the plasma Aβ1-42/Aβ1-40 ratio as a single premorbid biomarker for dementia. 
This fits the notion that biomarker profiles rather than single biomarkers are likely required 
to accurately identify persons at risk of dementia.10 Our data support that biomarkers can be 
identified in plasma and may play an important role in dementia-risk profiling of presymp-
tomatic individuals. Moreover, our findings illustrate that risk profiles may differ according 
to the development stage of the underlying disease process. Time-to-event may become 
an important factor to take into account when developing biomarker panels to screen for 
presymptomatic dementia.
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The main objective of the research described in this thesis was to gain insight in the role 
of potentially modifiable determinants of cognitive decline and dementia in the elderly. I 
specifically focused on the role of glucose metabolism, vascular and inflammatory mecha-
nisms and the influence of genetic factors on the pathogenesis of cognitive impairment and 
dementia, and additionally investigated preclinical biomarkers that have been suggested to 
be useful in the identification of people at risk for cognitive impairment and dementia.
In this chapter, I will first discuss some methodological considerations that apply to the 
studies described in this thesis. Second, the main findings of the research are addressed, 
and I will discuss how they relate to current knowledge on the development of cognitive 
impairment and dementia in the elderly. Finally, I will evaluate the clinical implication of 
these findings and suggest some directions for future research.
metHodologicAl considerAtions
How to measure cognitive function
In recent years, the amount of research on cognitive function and decline in the general 
population has rapidly increased. Interest in the pathophysiology of cognitive impairment 
has lead to a number of large population-based studies that examined the relation between 
potential risk factors and cognitive function and decline.1-4 This increasing attention for 
studying cognitive function and decline is a positive development, although the great 
variety in neuropsychological tests that are used sometimes obstructs the comparability of 
results across studies: apart from the Mini-Mental State Examination,5 there is little overlap 
in cognitive tests between studies. If consensus could be reached upon the use of some 
specific neuropsychological tests to assess distinct domains of cognitive function in these 
large, population-based studies, this would make it easier to compare results across stud-
ies. Fortunately, this issue was less of a problem in the studies discussed in this thesis (the 
Rotterdam Study, the Leiden 85-plus Study and PROSPER) as the neuropsychological test 
batteries in the different populations were quite comparable.
Selective attrition
Although research on determinants of cognitive decline and dementia in the very old is 
expanding, in most studies there is a clear underrepresentation of oldest old individuals. 
Extrapolating results from younger persons may be unwarranted in light of recent findings 
that suggest that risk factors that play a role at younger ages are not important anymore 
when people survive until higher ages.6,7 Large numbers of very old participants are needed 
to study the potentially age-specific effects of possible risk factors for cognitive decline and 
dementia.
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Furthermore, it is well recognized that epidemiologic studies of aging-related conditions 
can suffer from potentially large selection bias. Selective attrition in these studies of old 
people could affect the age-specific risk estimates, comparison between studies, and biologi-
cal interpretation of the results.8 This phenomenon may also have played a role in some of 
the studies presented in this thesis. For instance, in the investigation of the relation between 
blood pressure and cognitive function later in life, participants with a relatively low blood 
pressure and good cognitive function at baseline were more likely to be included in the study 
sample than participants with higher blood pressure and worse cognitive function at base-
line. Selective attrition could have influenced our results, especially in the oldest age group 
of the Rotterdam Study where a large proportion of the participants who were present at 
baseline were not available at follow-up anymore. This was one of the reasons for combining 
our results on the relation between blood pressure and cognitive function from the Leiden 
85-plus Study with those from the Rotterdam Study.
Cross-sectional vs. longitudinal study design
It is a generally accepted view that cross-sectional data are inferior to longitudinal data, as 
they would not allow for causal inference. In chapter 2.1, I presented the results of our inves-
tigation of the influence of selection by health and survival on estimates of age-associated 
cognitive function, and showed how this phenomenon influences both cross-sectional and 
longitudinal study designs. Although the causality of a relation may be difficult to infer from 
cross-sectional data, our findings indicated that the same selective mechanisms apply to 
longitudinal data. In a cross-sectional study participation may be selective as healthy people 
tend to have higher participation rates, yet longitudinal estimates will be based on a further 
selection of these healthy participants at baseline: those who complete follow-up. The choice 
for a longitudinal study design will therefore not necessarily provide a superior estimate of 
age-associated cognitive function over a cross-sectional design, as the influence of health 
related selection should be carefully taken in consideration in the assessment of cognitive 
function using either design.
mAin reseArcH Findings
Measuring cognitive function
In chapter 2.1, I described our study on the measurement of cognitive function that showed 
that participants with complete follow-up were healthier and had better age-specific cogni-
tive scores than those with incomplete follow-up. This health selection influenced estimates 
of cognitive function and decline in both cross-sectional and longitudinal study designs. 
Furthermore, the length of follow-up affected the estimation of cognitive decline, with a 
short follow-up resulting in a larger estimated rate of decline than a longer follow-up. Even 
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advanced statistical models such as linear mixed models could not properly account for the 
selective attrition that was present.
Many studies have addressed the problem of defining meaningful estimates of cognitive 
decline in the presence of selective attrition or “censoring by death”, although it remains un-
clear which approach is most appropriate.9 Principal stratification,10 and “joint modeling” of 
both random effects in longitudinal covariates and the survival components,11 are suggested 
tools to deal with the selection bias in longitudinal epidemiological studies, but their useful-
ness in this specific setting needs further clarification. In an accompanying commentary to 
our paper, Hernán et al.8 showed how selection bias due to censoring by death can influence 
estimates in epidemiological studies. This further addresses the issue that selection on health 
and survival is often present in large epidemiological studies and has implications for com-
parison of estimates among studies as well as for biological interpretation of the results.8 In 
general, the assessment of cognitive function in the elderly requires sufficient consideration 
of the possible influence of selection by health and survival.
Glucose metabolism and cognitive function
Although diabetes mellitus has been shown to associate with an increased risk of dementia 
and cognitive decline,12-14 it is unclear if people in a “pre-diabetic” state, when impaired 
fasting glucose levels are present, already suffer from impaired cognitive function or an 
accelerated rate of cognitive decline.15-18 In our analyses of data on fasting glucose levels 
and cognitive function and decline in a large sample of participants from PROSPER and the 
Rotterdam Study (chapter 3.1), we could not find a clear relation between elevated fasting 
glucose levels or increased insulin resistance and cognitive function and decline in people 
without a history of diabetes. These data suggest that cognitive decline accelerates strongly 
once diabetic but not with lesser degrees of dysglycaemia. As a result, preventing individuals 
at risk from developing diabetes through lifestyle changes, may also lead to large societal 
gains by preventing such individuals from undergoing accelerated cognitive decline.
In chapter 3.2, I described how an evolutionary conserved pathway that is related to glucose 
metabolism associates with cognitive function in 1015 participants from both cohorts of the 
Leiden 85-plus Study. In accordance with previous findings on old age survival, we found that 
genetically reduced insulin/IGF-1 signaling (IIS) was associated with better cognitive function 
in women, but not in men. These current findings are in accordance with the available data 
from model organisms that showed favourable effects of genetically induced lower IIS activity 
on both life span and health span.19-21 Furthermore, the observed sex-specific involvement of 
IIS pathway activity in the development of cognitive impairment that we found, is supported 
by previous findings.19,22 It is possible that improved learning and memory play an important 
role in the success of seeking food elsewhere, which is especially important for the female 
sex, as females must obtain sufficient energy to support the survival and development of 
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their offspring as well as themselves. Suggested mechanisms that could underlie the relation 
between reduced IIS pathway activity and better cognitive function in females include in-
creased stress resistance, and reduced amyloid β-induced autophagosome accumulation,22-24 
although these results were mainly based on C.elegans data. To conclude, we showed that 
genetically reduced insulin/IGF-1 signaling seems to be beneficial for cognitive function in 
women, but not in men, which further indicates the involvement of the insulin/IGF-1 signal-
ing pathway in the regulation of health span.
Vascular and inflammatory factors and cognitive function
In chapter 4.1, I presented the results of our investigation on the relation between blood 
pressure and cognitive function, and more specifically the influence of age on this relation. 
Several studies have shown that higher blood pressure levels at middle-age relate to cogni-
tive impairment later in life,1,25-27 possibly as a result of atherosclerotic changes in large and 
small cerebral vessels, ischaemic brain lesions, or disturbances in endothelial or brain cell 
permeability.1,26,28 However, notwithstanding a vast amount of investigations, there is no gen-
eral agreement on the relation between blood pressure and later cognitive function across 
different age groups.28 Conflicting results in old aged participants have lead to the sugges-
tion that age might influence the relation between blood pressure and cognitive function in 
the sense that blood pressure might not be a risk factor for cognitive impairment anymore in 
the oldest age categories. Moreover, three of four large trials of antihypertensive medication 
with dementia as a secondary endpoint that have been published did not find a reduction in 
incidence of dementia in the treatment group.29-32
We found in combined analyses of data from the Rotterdam Study and the Leiden 85-plus 
Study that indeed, higher blood pressure levels were associated with worse cognitive func-
tion later in life in participants aged up to 74 years, but that this relation reversed in older 
participants. In the oldest old, higher blood pressure was related to better cognitive function 
later in life. Although the possible influence of selective attrition on our results should not 
be ignored, there are other mechanisms that could underlie these findings. An alterna-
tive explanation is that in the oldest old a higher blood pressure is necessary to maintain 
adequate cerebral perfusion.33-35 With increasing age, basal cerebral blood flow decreases, 
possibly caused by impaired cerebral autoregulation through atherosclerosis or endothelial 
dysfunction.36,37 In the oldest old, a higher blood pressure may therefore be required to pre-
vent cerebral hypoperfusion and preserve cognitive function. Results from the HYVET-trial, a 
randomised, placebo-controlled trial that included only participants of 80 years or over, did 
not show beneficial effects of antihypertensive treatment on incidence of dementia.38
In conclusion, we found that the relation between baseline blood pressure levels and cog-
nitive function later in life differs across age groups. High blood pressure is a risk factor for 
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cognitive impairment up to age 75 years but may preserve cognitive function thereafter. Risks 
and benefits of blood pressure lowering therapy in the oldest old have to be determined.
Inflammation has repeatedly been suggested to play a role in the development of dementia 
and cognitive impairment by several lines of investigation. Animal models showed a relation 
between proinflammatory cytokines and neurodegeneration,39 and inflammatory markers 
were found in the neighbourhood of senile plaques in the brain of demented persons.40 More-
over, higher levels of circulating inflammatory markers were associated with an increased 
risk of dementia in population-based studies.41,42 How these inflammatory markers relate to 
cognitive function and decline in the early stages of the development of dementia is not yet 
clear. In chapter 4.2, I described the results of our investigation on the association between 
inflammatory markers and cognitive function and decline in combined analyses of data from 
the Rotterdam Study and the Leiden 85-plus Study. We showed that systemic markers of 
inflammation were only moderately associated with cognitive function and decline.
Serum uric acid is known as an independent risk factor for myocardial infarction, stroke, and 
cardiovascular mortality,43-45 that exerts its damage through mechanisms such as stimulation 
of vascular smooth muscle cell proliferation; its inflammatory properties; and a direct effect 
on endothelial function by impairing nitric oxide production.43,44,46 Remarkably enough, as a 
major natural antioxidant, uric acid also accounts for a substantial part of the antioxidative 
capacity of the plasma.47 This beneficial property might reduce oxidative stress and protect 
against the detrimental effect of free radicals. In the development of cognitive impairment 
and dementia, both vascular pathology and oxidative stress are involved.48-50 Therefore, the 
different properties of uric acid might have contradictory effects on the risk of dementia and 
on cognitive function. In chapter 4.3, we studied the relation between serum uric acid levels 
and the risk of dementia as well as the relation between serum uric acid levels and several 
domains of cognitive function later in life, in the Rotterdam Study. We found in an overall 
analysis that serum uric acid levels were not associated with the risk of dementia or with cog-
nitive function later in life. However, after adjustment for several cardiovascular risk factors, 
the protective effect of uric acid was unmasked and higher serum uric acid levels were associ-
ated with a decreased risk of dementia and better cognitive function later in life. Although 
these findings are not in line with a previous study that associated increased serum uric acid 
levels with worse cognitive function in a cross-sectional sample of community dwelling par-
ticipants, we were to our knowledge the first to assess the relation between serum uric acid 
and cognitive function and dementia in a prospective, population-based design with a large 
study sample and a vast number of cardiovascular risk factors that were assessed.
In conclusion, we found that higher serum uric acid levels are related to a decreased risk 
of dementia and better cognitive function later in life, but only after adjustment for several 
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cardiovascular risk factors. This corroborates the notion that oxidative stress is involved in the 
pathogenesis of dementia and cognitive impairment.
Markers for cognitive decline
In chapter 5.1, I described the results of our investigation of the role of plasma amyloid β 
peptides as potential biomarkers for the risk of dementia and cognitive decline at large.
Senile plaques in the brain of Alzheimer’s disease (AD) patients are a characteristic hall-
mark of the disease.51 These plaques predominantly contain amyloid β (Aβ) peptides that are 
derived from the amyloid β precursor protein (APP) by proteolytic processing.52 The majority 
of these Aβ peptides contain 40 amino acids (Aβ1-40) but a small part consists of 42 amino 
acids (Aβ1-42). This Aβ1-42 peptide is the major constituent of the senile plaques and is thought 
to deposit first in the disease process, before Aβ1-40.
53-55 Aβ peptides have been detected in 
cerebral spinal fluid (CSF), urine, skin and plasma.56-58 Although the brain is considered as 
the origin of the deposited Aβ in the senile plaques, the source of Aβ peptides in the plasma 
remains unclear.59 APP is produced by a variety of cells in and outside the brain, including 
platelets that could influence plasma Aβ levels.60 It is unknown how the deposition of Aβ in 
the brain affects plasma Aβ levels, but a complex equilibrium between brain deposition and 
plasma levels of the Aβ peptides is suggested.61-63 Plasma levels of Aβ peptides increase with 
age and increased plasma levels of Aβ peptides have been found in patients with early-onset, 
familial Alzheimer’s disease and in patients with Down’s syndrome, who are at higher risk of 
developing Alzheimer’s disease.64-66
A previous study has shown that elevated plasma levels of Aβ peptides are associated with 
the development of dementia.59 Furthermore, it was shown that plasma Aβ1-42 levels selec-
tively decline in the presymptomatic period of the disease, possibly reflecting the deposition 
of Aβ1-42 in the brain.
59,67 In a recent study, Graff-Radford and colleagues postulated that a 
lower ratio of Aβ1-42/Aβ1-40 could indicate this selective decline of Aβ1-42 in the presymptomatic 
period of the disease. They found an association between a lower plasma ratio of Aβ1-42/Aβ1-40 
and an increased risk of dementia, and suggested the use of the plasma Aβ1-42/Aβ1-40 ratio as 
a premorbid biomarker to identify individuals at risk for developing Alzheimer’s disease.68 
Our previous findings in a case-cohort study embedded in the Rotterdam Study showed that 
a lower plasma ratio of Aβ1-42/Aβ1-40 was associated with an increased risk of dementia, in 
accordance with the findings of Graff-Radford and colleagues.69
We considered that if the plasma Aβ1-42/Aβ1-40 ratio indeed reflects the selective deposi-
tion of Aβ1-42 in the brain, it might be a relatively late marker in the presymptomatic stages 
of the disease. Furthermore, we hypothesized that although the plasma Aβ1-42/Aβ1-40 ratio 
can mark an increased risk of dementia, it may not or less associate with earlier stages of 
presymptomatic disease.
The results that I presented in chapter 5.1 showed that although a lower plasma Aβ1-42/
Aβ1-40 ratio was associated with a higher risk of incipient dementia, this risk diminished with 
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increasing time-to-event. Furthermore, the plasma Aβ1-42/Aβ1-40 ratio was not associated with 
the risk of cognitive decline in persons who did not develop dementia during follow-up. 
These findings suggest that although the plasma Aβ1-42/Aβ1-40 ratio may mark a relatively late 
stage in the preclinical development of dementia, it is not an adequate marker for the risk 
of dementia or cognitive decline in earlier stages of the preclinical disease process. Our data 
support the notion that biomarkers can be identified in plasma and may play an important 
role in dementia-risk profiling of presymptomatic individuals. Moreover, our findings il-
lustrate that risk profiles may differ according to the development stage of the underlying 
disease process. Time-to-event may become an important factor to take into account when 
developing biomarker panels to screen for presymptomatic dementia.
clinicAl imPlicAtions
One of the main messages with clinical relevance that arises from the research presented in 
this thesis is that the oldest old might differ more from younger individuals with respect to 
the mechanisms that underlie the development of cognitive impairment than is recognized 
at this moment. Some reluctance in the extrapolation of research results based on relatively 
young populations to the oldest old participants is warranted, as is shown in our study on 
blood pressure and cognitive function that indicates that current dogma of “lower is better” is 
not supported by our data on cognitive function in the elderly. These observational findings 
are supported by the results from the placebo-controlled clinical trials of antihypertensive 
medication with incidence of dementia or cognitive function as an outcome that all but one 
did not show a protective effect on cognitive function in the treatment group.29-32 Recent 
findings from the HYVET-trial, that included only participants of 80 years or over, did not show 
beneficial effects of antihypertensive treatment on incidence of dementia.38 Therefore, some 
reservation in the treatment of high blood pressure in the oldest old might be appropriate.
The results of our examination of fasting glucose levels in relation to cognitive function 
and decline showed that although diabetes mellitus is associated with impaired cognitive 
function, this is not the case for increased levels of fasting glucose. Suggestions to screen 
individuals for impaired fasting glucose levels based on their supposedly increased risk 
on cognitive impairment in this “pre-diabetic” state could not be supported by our data. 
However, preventing individuals at risk from developing diabetes through lifestyle changes, 
may lead to large societal gains by preventing such individuals from undergoing accelerated 
cognitive decline.
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FUtUre reseArcH
The work described in this thesis has provided additional insights in the relation between 
several potential risk factors for cognitive decline and dementia in the very old and I have 
tried to address and dispute several dogmas that were encountered.
The main message that can be derived from this work and which should be implemented 
in future research is that despite the well recognized potential gain in experienced health of 
the oldest old in our population from new insights in the development of cognitive decline 
and dementia, studies on this subject have not yet been placed in the limelight they deserve. 
Although there seems to be a general consensus that focus in research should lie on those 
biological mechanisms that are involved in the development of cognitive impairment in 
especially the oldest old, as the occurrence of cognitive impairment is predominantly present 
in the oldest people, the highest age groups remain to be underrepresented in most studies. 
Suggestions of age-specific relations of risk factors for cognitive decline and dementia, such 
as blood pressure, further emphasize the need for study samples in which the oldest old are 
sufficiently represented.
One of the methodological considerations that should be taken into account in future re-
search is the vast amount of different neuropsychological tests that are being used in the 
investigation of determinants of cognitive impairment. The variability in tests designed 
to measure distinct domains of cognitive function may on the one hand increase the un-
derstanding of the relation between potential risk factors and cognitive function, but also 
makes the comparability of results across studies more difficult. Discussing the usefulness 
and appropriateness of the currently available tests in the prospect of reaching some sort of 
general agreement on neuropsychological tests may render more effect than the continuous 
development of additional tests.
Furthermore, our findings on the methodology of measuring cognitive function, and more 
specifically the influence of selection on health and survival in studies on age-associated 
cognitive function showed that there is still some ground to be covered in clarifying the 
methodological issues that can affect the estimation of cognitive function. There are indica-
tions that longer follow-up periods are needed in studies on cognitive decline, to minimize 
the potential learning effect between examinations. However, longer follow-up will most 
likely result in an increased number of participants who drop out before the end of follow-up, 
as our findings showed. The current inability to appropriately deal with the selective attrition 
that is present in studies on cognitive function and decline, through the handling of multiple 
and missing data with advanced statistical modeling, emphasizes the importance to investi-
gate the influence of phenomena such as selection on health and survival on the estimation 
of cognitive function in these studies.
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The shift in focus from the clinical endpoint of the dementia syndrome to studying changes 
in cognitive function in the developmental stages of the disease, that we made in the re-
search described in this thesis, could be expanded even further. Increasing technological 
development in the imaging field has lead to the possibility to study subtle changes in brain 
structures that could underlie the first indication of cognitive decline that is not detected 
by neuropsychological testing. Investigating the relation between potential risk factors for 
dementia and cognitive decline and these structural brain changes, in combination with 
the effect of these changes on cognitive function in a later stage of the development of the 
disease could provide more insight in the biological mechanisms that underlie the eventually 
appearing cognitive impairment.
Finally, a better understanding of the impact of changes in cognitive abilities on the individu-
ally experienced quality of daily life of people may help in the choice for further research 
directions from a more clinical point of view. The research described in this thesis was mainly 
based on investigating the biological mechanisms that could underlie the development of 
cognitive impairment, although the personally experienced deprivation of cognitive abilities 
does not have to correspond fully with the decline in neuropsychological test scores. The 
identification of those cognitive domains that seem to have greatest impact on daily living 
might give us more insight in studying specific domains of cognition with respect to clinical 
relevance.
Chapter 6
122
reFerences
 1. Launer LJ, Masaki K, Petrovitch H et al. The association between midlife blood pressure levels and 
late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274: 1846-1851.
 2. Elias MF, Wolf PA, D’Agostino RB et al. Untreated blood pressure level is inversely related to cogni-
tive functioning: the Framingham Study. Am J Epidemiol 1993;138: 353-364.
 3. Waldstein SR, Giggey PP, Thayer JF et al. Nonlinear relations of blood pressure to cognitive func-
tion: the Baltimore Longitudinal Study of Aging. Hypertension 2005;45: 374-379.
 4. Butler SM, Ashford JW, Snowdon DA. Age, education, and changes in the Mini-Mental State Exam 
scores of older women: findings from the Nun Study. J Am Geriatr Soc 1996; 44: 675-681.
 5. Folstein MF, Folstein SE, McHugh PR. „Mini-mental state“. A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
 6. Van Bemmel T, Gussekloo J, Westendorp RGJ, Blauw GJ. In a population-based prospective 
study, no association between high blood pressure and mortality after age 85 years. J Hypertens 
2006;24:287-92.
 7. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RGJ. High-density vs 
low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old 
age. Arch Intern Med 2003;163:1549-54.
 8. Hernán MA, Alonso A, Logriscino G. Cigarette smoking and dementia; potential selection bias in 
the elderly. Epidemiology; 19: 448-450.
 9. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002;58:21-29.
 10. Rubin DB. Comment on «Causal inference without counterfactuals,» by AP Dawid. J Am Stat Ass 
2000;95:435-437.
 11. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. 
Biometrics 1997;52:330-339.
 12. Ott A, Stolk RP, Van Harskamp F, Pols HAP, Hofman A, Breteler MMB. Diabetes mellitus and the risk 
of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
 13. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabetic 
Medicine 1999; 16: 93-112.
 14. Grodstein F, Wilson RS, Chen J, Manson JE. Type 2 diabetes and cognitive function in community-
dwelling elderly women. Diabetes Care 2001; 24: 1060-1065.
 15. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barret-Connor E, Krueger K. Diabetes, impaired 
fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 
658-663.
 16. Fontbonne A, Ducimetière P, Berr C, Alpérovitch. Changes in cognitive abilities over a 4-year pe-
riod are unfavorably affected in elderly diabetic subjects. Results of the Epidemiology of Vascular 
Aging Study. Diabetes Care 2001; 24: 366-370.
 17. Kanaya AM, Barret-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose 
tolerance status in older adults. A 4-year prospective study of the Rancho Bernardo Study Cohort. 
Arch Intern Med 2004; 164: 1327-1333.
 18. Fuh JL, Wang SJ, Hwu CM, Lu SR. Glucose tolerance status and cognitive impairment in early 
middle-aged women. Diabetic Med 2007; 24: 788-791.
 19. Johnson TE. Increased life-span of age-1 mutants in Caenorhabditis elegans and lower Gompertz 
rate of aging. Science. 1990;249: 908-912.
 20. Kenyon C. A conserved regulatory system for aging. Cell 2001;105:165-168.
123
General discussion
Ch
ap
te
r 6
 21. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science 
2003;299:1346-1351.
 22. Martin B, Pearson M, Kebejian L, et al. Sex-dependent metabolic, neuroendocrine, and cognitive 
responses to dietary energy restriction and excess. Endocrinology. 2007;148:4318-4333.
 23. Florez-McClure ML, Hohsfield LA, Fonte G, Bealor MT, Link CD. Decreased insulin-receptor sig-
naling promotes the autophagic degradation of β-amyloid peptide in C. elegans. Autophagy. 
2007;3:569-580.
 24. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-
onset proteotoxicity. Science. 2006;313:1604-1610.
 25. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in 
middle-age in the Whitehall II study. J Clin Epidemiol 2005;58:1308-1315.
 26. Elias MF, Wolf PA, D’Agostino RB et al. Untreated blood pressure level is inversely related to cogni-
tive functioning: the Framingham Study. Am J Epidemiol 1993;138(6):353-364.
 27. Kilander L, Nyman H, Boberg M et al. Hypertension is related to cognitive impairment: a 20-year 
follow-up of 999 men. Hypertension 1998;31:780-786.
 28. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive func-
tion and dementia. Lancet Neurol 2005;4:487-499.
 29. Forette F, Seux M-L, Staessen J, et al. Prevention of dementia in randomised double-blind placebo-
controlled sustolic hypertension in Europe (Syst-Eur) trial. Lancet 1998 ;352 :1347-1351.
 30. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function on cognitive and car-
diovascular outcomes : study on cognition and prognosis in the elderly (SCOPE)-a randomized 
double-blind trial. Am J Hypertens 2005 ;18 :1052-1059.
 31. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension 
on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern 
med 1994;154:2154-2160.
 32. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and 
indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. 
Arch Intern Med 2003;163:1069-1075.
 33. Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rot-
terdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001;12:33-39.
 34. Ruitenberg A, den Heijer T, Bakker SL, et al. Cerebral hypoperfusion and clinical onset of dementia: 
the Rotterdam Study. Ann Neurol 2005;57:789-794.
 35. Spilt A, Weverling-Rijnsburger AWE, Middelkoop HAM, et al. Late-onset dementia: structural brain 
damage and total cerebral blood flow. Radiology 2005;236:990-995.
 36. Buijs PC, Krabbe-Hartkamp MJ, Bakker CJ, et al. Effect of age on cerebral blood flow: measure-
ment with ungated two-dimensional phase-contrast MR angiography in 250 adults. Radiology 
1998;209:667-674.
 37. Kamper AM, Spilt A, de Craen AJM et al. Basal cerebral blood flow is dependent on the nitric oxide 
pathway in elderly but not in young healthy men. Exp Geront 2004;39:1245-1248.
 38. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hy-
pertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, 
placebo controlled trial. Lancet Neurol 2008;8:683-689.
 39. Campbell IL, Stalder AK, Chiang CS et al. Transgenic models to assess the pathogenic actions of 
cytokines in the central nervous system. Mol Psychiatry 1997;2:125-129.
 40. Eikelenboom P, Veerhuis R. The importance of inflammatory mechanisms for the development of 
Alzheimer’s disease. Exp Gerontol 1999;34:453-461.
Chapter 6
124
 41. Schmidt R, Schmidt H, Curb JD et al. Early inflammation and dementia: a 25-year follow-up of the 
Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174.
 42. Engelhart MJ, Geerlings MI, Meijer J et al. Inflammatory proteins in plasma and the risk of demen-
tia: the rotterdam study. Arch Neurol 2004;61:668-672.
 43. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality; The NHANES I epidemiologic 
follow-up study, 1971-1992. JAMA 2000; 283: 2404-10.
 44. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid as 
a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort 
study. Arch Intern Med 2004; 164: 1546-1551.
 45. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocar-
dial infarction and stroke; The Rotterdam Study. Stroke 2006; 37: 1503.
 46. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic 
role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 
1183-90.
 47. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring anti-
oxidant capacity and its application to monitoring the antioxidant status in premature neonates. 
Clin Sci 1993; 84: 407-12.
 48. Breteler MMB. Vascular risk factors for Alzheimer disease. Neurobiol Aging 2000; 21: 153-60.
 49. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 621S-629S.
 50. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol 
2004; 3: 219-26.
 51. Selkoe DJ. Alzheimer;s disease: a central role for amyloid. J Neuropathol Exp Neurol 1994;53:438-
447.
 52. Selkoe DJ. Molecular pathology of Alzheimer’s disease: the role of amyloid. In: Growden J, Rossor 
M, eds. The Dementias. Woburn, Mass: Butterworth-Heinemann; 1998:257-283.
 53. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (Aβ) in Alzheimer’s disease brain: bio-
chemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or 
Aβ42(43). J Biol Chem 1995;270:7013-7016.
 54. Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer’s disease. Ann Neurol 
1995;37:287-288.
 55. Iwatsubo T, Mann DM, Odaka A, et al. Amyloid beta protein (A beta) deposition: A beta 42(43) 
precedes A beta 40 in Down syndrome. Ann Neurol 1995;37:294-299.
 56. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with 
sporadic Alzheimer’s disease. J Neurol Sci 1996;141:65-68.
 57. Gisho J, Calero M, Matsubara E, et al. Alzheimer’s soluble amyloid beta is a normal component of 
human urine. FEBS Lett 1997;408:105-108.
 58. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Azheimer’s 
disease. Ann Neurol 1999;46:412-416.
 59. Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease; 
relation to age, mortality and risk. Neurology 2003;61:1185-1190.
 60. Skovronsky DM, Lee VM, Pratico D. Amyloid precursor protein and amyloid beta peptide in hu-
man platelets. Rol eof cyclooxygenase and protein kinase C. J Biol Chem 2001;276:17036-17043.
 61. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma 
amyloid beta protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci 
2001;21:372-381.
125
General discussion
Ch
ap
te
r 6
 62. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux; a measure of brain 
amyloid burden in a mouse model of Alzheimer’s disease. Science 2002;295:2264-2267.
 63. Deane R, Du Yan S. Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across 
the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-913.
 64. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta protein similar to that in the senile 
plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations 
linked to familial Alzheimer’s disease. Nat Med 1996;2:864-870.
 65. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of 
dementia in adults Down syndrome. Neurosci Lett 2001;301:199-203.
 66. van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid beta, apoliprotein E, lacunar infarcts, and 
white matter lesions. Ann Neurol 2004;55:570-575.
 67. Graff-Radford N. Analysis of plasma Aβ42 as a premorbid marker for late onset Alzheimer’s dis-
ease. Neurobiol Aging 2004;25;354.
 68. Graff-Radford N, Crook JE, Lucas J, et al. Association of low plasma Aβ1-42/ Aβ1-40 ratios with 
increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 
2007;64:354-362.
 69. van Oijen M, Hofman A, Soares HD, et al. Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a 
prospective case-cohort study. Lancet Neurol 2006;5:655-660.

7
Summary

129
7.1
Summary (in English)
The devastating impact of the loss of cognitive abilities that often accompanies the aging 
process is feared by many. Despite an increasing number of studies, the precise etiology of 
the disease is not known yet. There is accumulating evidence that a variety of causes, rather 
than a single factor, result in impaired cognitive function and the clinical symptoms of de-
mentia. Glucose metabolism, vascular pathology and inflammation have all been suggested 
to play a role in the development of cognitive impairment and dementia.
The main objective of the work described in this thesis was the investigation of potentially 
modifiable risk factors, including factors involved in glucose metabolism, vascular pathology 
and inflammation in especially the early stages of the disease process. Furthermore, there have 
been studies that suggested that in general, possible risk factors that play a role at younger 
ages may not be important anymore when people survive until higher ages. Therefore, I ad-
ditionally studied the age-specific effects of these risk factors in several large prospective 
studies including the Rotterdam Study, the Leiden 85-plus Study, and the PROSPER study, 
that were complementary with respect to the age of the participants and consequently al-
lowed me to study the association between several potentially modifiable risk factors and 
cognitive function and decline over a wide age range in the general population. Finally, I 
investigated suggested preclinical biomarkers of dementia that might be used to identify 
people who are at increased risk of developing dementia.
I first explored the measurement of cognitive function, with respect to the effect of selection 
by health and survival on the estimation of cognitive function and decline in epidemio-
logical studies. chapter 2 showed that selection for health and survival resulted in better 
age-specific cognitive test scores and less cognitive decline, and that this selection affects 
both cross-sectional and longitudinal studies. Subsequently, statistical methods handling 
multiple and missing data did not seem to fully correct for this bias. These results indicated 
that assessments of cognitive function in the elderly must take particular care in considering 
possible biases from health selection.
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In chapter 3, the results from studies on the relation between glucose metabolism and 
cognitive function were presented. First, I investigated the influence of fasting glucose levels 
and insulin resistance on cognitive function in non-diabetic elderly from two independent 
prospective studies: the PROSPER study and the Rotterdam Study (chapter 3.1). Elevated 
fasting glucose levels and insulin resistance were not associated with worse cognitive func-
tion or a higher rate of cognitive decline in elderly subjects without a history of diabetes. 
These data suggest either a threshold for effects of dysglycaemia on cognitive function, or 
that factors other than hyperglycaemia-related pathways impair cognition in individuals with 
frank diabetes. In chapter 3.2, I described the relation between genetically reduced insulin/
IGF-1 signaling (IIS) and cognitive function and decline, in participants from the Leiden 85-
plus Study, aged 85 years and over. In addition to old age survival, genetically reduced IIS 
seemed to be beneficial for cognitive function in women.
chapter 4 described the relation between vascular and inflammatory factors and cognitive 
function and decline. In chapter 4.1, I evaluated the age-specificity of the relation between 
blood pressure and cognitive function by examining the relationship between baseline blood 
pressure and cognitive function later in life across age groups. The data showed that high 
blood pressure increased the risk of cognitive impairment up to 75 years, but was associated 
with better cognitive function thereafter. This could mean that age-specific guidelines for 
blood pressure management are needed, as the current directive that ’lower is better’ may 
not apply to blood pressure levels in the very old. In chapter 4.2, I investigated the relation 
between inflammatory markers and cognitive impairment in the early stages of the develop-
ment of dementia, and found that systemic markers of inflammation were only moderately 
associated with cognitive function and decline. chapter 4.3 described the relation between 
serum uric acid, a cardiovascular risk factor as well as a major natural antioxidant, and the risk 
of dementia and cognitive impairment. The results showed that notwithstanding the associ-
ated increased risk of cardiovascular disease, higher levels of uric acid were associated with a 
decreased risk of dementia and better cognitive function later in life.
chapter 5 showed the investigation of potential preclinical biomarkers of dementia. In 
chapter 5.1, I described the relation between plasma Aβ1-42 and Aβ1-40 levels and the risk of 
dementia and evaluated the influence of time-to-event on this relation. Additionally, I studied 
the relation between plasma Aβ1-42 and Aβ1-40 levels and the risk of cognitive decline in those 
who remained free of dementia. It seemed that the risk of dementia associated with a lower 
plasma Aβ1-42/Aβ1-40 ratio was particularly increased within the first years after the biomarker 
assessment. There was no association between the plasma Aβ1-42/Aβ1-40 ratio and the risk of 
cognitive decline in those who did not develop dementia. This indicates that assessment 
of the plasma Aβ1-42/Aβ1-40 ratio alone is not sensitive enough to identify people at risk for 
cognitive decline at large.
In chapter 6, I evaluated the several methodological issues that were related to the work 
described in this thesis and discussed some suggestions for further research.
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Het verwoestende effect van het verlies van het cognitieve vermogen, dat vaak samen 
gaat met het ouder worden, wordt door velen gevreesd. Ondanks een toenemend aantal 
studies is de exacte oorzaak van het achteruitgaan van de cognitie nog niet bekend. Het 
lijkt er steeds meer op dat het eerder een verzameling van oorzaken is en niet een enkele 
factor die leidt tot een verslechterende cognitie en de klinische symptomen van dementie. 
Glucose metabolisme, vasculaire mechanismen en inflammatie-processen zijn gesuggereerd 
als mogelijke factoren die hierbij een rol kunnen spelen.
De belangrijkste doelstelling van dit proefschrift is het onderzoeken van potentiële risico-
factoren, zoals factoren die betrokken zijn bij het glucose metabolisme, vasculaire patholo-
gie en inflammatie in met name de vroege stadia van het ziekteproces. Er zijn onderzoeken 
bekend die suggereren dat bepaalde risicofactoren die een rol spelen op jongere leeftijd, 
wellicht minder belangrijk zijn wanneer mensen op hogere leeftijd zijn. Ik heb daarom de 
mogelijke leeftijdsspecificiteit van deze risicofactoren onderzocht in verschillende, grote, 
prospectieve studie-cohorten, zoals de Rotterdam Studie, de Leiden 85-plus Studie en de 
PROSPER studie. Deze cohorten zijn aanvullend met betrekking tot de leeftijd van de deel-
nemers en boden daarmee de mogelijkheid om de relatie tussen potentiële risicofactoren 
en cognitieve functie en achteruitgang te bestuderen in verschillende leeftijdsgroepen in 
de algemene bevolking. Tenslotte heb ik enkele preklinische biomarkers voor dementie 
onderzocht die mogelijk gebruikt zouden kunnen worden om mensen te identificeren die 
een verhoogd risico lopen om dementie te ontwikkelen.
Ten eerste heb ik het meten van cognitieve functie onderzocht, met betrekking tot de in-
vloed van selectie op gezondheid en overleven op de schatting van cognitieve functie en 
achteruitgang in epidemiologische onderzoeken. Hoofdstuk 2 laat zien dat deze selectie op 
gezondheid en overleven resulteert in bettere leeftijdsspecifieke cognitieve test scores en 
minder cognitieve achteruitgang, en dat deze selectie een rol speelt in zowel cross-sectionele 
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als longitudinale onderzoeken. Vervolgens bleek ook dat statistische methodes die gebruikt 
worden om met meerdere metingen en missende data om te gaan, niet geheel corrigeren 
voor de verstoring door deze selectie. Deze resultaten suggereren dat er bij het bepalen van 
cognitive functie bij ouderen rekening moet worden gehouden met de mogelijke verstoring 
door selectie op gezondheid en overleving.
In hoofdstuk 3 worden de resultaten van studies naar de relatie tussen glucose metabolis-
me en cognitieve functie gepresenteerd. In eerste instantie heb ik de invloed onderzocht van 
de glucose concentratie in het bloed en van insuline resistentie, op de cognitieve functie van 
ouderen die geen diabetes hadden. Dit is onderzocht in twee onafhankelijke, prospectieve 
cohorten: de PROSPER studie en de Rotterdam Studie (hoofdstuk 3.1). Verhoogde glucose 
concentraties en insuline resistentie waren niet geassocieerd met slechtere cognitieve func-
tie of met een snellere cognitieve achteruitgang bij ouderen die geen diabetes hadden. Deze 
resultaten suggereren dat er oftewel een drempelwaarde bestaat voor effecten van dysgly-
caemie op cognitieve functie, of dat er andere factoren dan hyperglycaemie-gerelateerde 
mechanismen de cognitieve functie van mensen met langdurige diabetes beïnvloeden. In 
hoofdstuk 3.2 heb ik de relatie beschreven tussen genetisch gereduceerde insuline/IGF-1 
stimulatie (IIS) en cognitieve functie en achteruitgang, in deelnemers van de Leiden 85-plus 
Studie, die 85 jaar en ouder waren. Hieruit bleek dat een genetisch gereduceerde IIS naast 
een overlevingsvoordeel op hoge leeftijd ook gunstig lijkt te zijn voor cognitieve functie bij 
vrouwen.
Hoofdstuk 4 beschrijft de relatie tussen vasculaire en inflammatoire factoren, en cognitieve 
functie en achteruitgang. In hoofdstuk 4.1, heb ik de de leeftijdsspecificiteit onderzocht van 
de relatie tussen bloeddruk en cognitieve functie, door deze relatie te bekijken in verschil-
lende leeftijdsgroepen van deelnemers. De data lieten zien dat hoge bloeddruk gerelateerd 
was aan slechtere cognitie tot aan een leeftijd van 75 jaar, maar dat op hogere leeftijden 
hoge bloeddruk gerelateerd was aan betere cognitieve functie. Dit kan betekenen dat er leef-
tijdsspecifieke voorschriften nodig zijn voor de behandeling van hoge bloeddruk, aangezien 
het huidige dogma “lager is beter” wellicht geen betrekking heeft op de bloeddruk van de 
oudste ouderen. In hoofdstuk 4.2 staan de resultaten beschreven van het onderzoek naar 
de relatie tussen inflammatoire markers en cognitieve functie in het vroege stadium van de 
ontwikkeling van dementie. Dit onderzoek laat zien dat er slechts een bescheiden relatie tus-
sen inflammatoire markers en cognitieve functie en achteruitgang is. In hoofdstuk 4.3 heb 
ik de relatie onderzocht tussen ureumzuur (een cardiovasculaire risicofactor maar ook een 
belangrijke antioxidant) en het risico op dementie en een slechtere cognitie. Deze resultaten 
lieten zien dat ondanks het verhoogde risico op cardiovasculaire ziekte, hogere concentraties 
van ureumzuur geassocieerd waren met een lager risico op dementie en betere cognitieve 
functie.
Hoofdstuk 5 laat het onderzoek zien van enkele potentiële preklinische biomarkers voor 
dementie. In hoofdstuk 5.1 beschrijf ik de associatie tussen plasma Aβ1-42 en Aβ1-40 con-
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centraties en het risico op dementie en evalueer ik de invloed van de tijd tot de diagnose 
dementie op deze relatie. Daarnaast heb ik de relatie onderzocht tussen deze plasma Aβ1-42 
en Aβ1-40 concentraties en het risico op een verstoorde cognitieve functie, in degenen die 
geen dementie ontwikkelden. Het bleek dat het risico op dementie dat geassocieerd was met 
een lagere Aβ1-42/Aβ1-40 ratio voornamelijk verhoogd was in de eerste jaren na het meten van 
de biomarkers. In degenen die geen dementie ontwikkelden was er geen relatie tussen de 
Aβ1-42/Aβ1-40 ratio en cognitieve functie. Dit lijkt erop te wijzen dat de bepaling van de Aβ1-42/
Aβ1-40 ratio alleen niet gevoelig genoeg is om mensen te identificeren die een verhoogd risico 
op dementie lopen.
In hoofdstuk 6.1 heb ik verschillende methodologische kwesties besproken die aan dit 
werk gerelateerd zijn en heb ik enkele voorstellen voor toekomstig onderzoek gedaan.
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